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A model storage condition was developed in the livers of mice by the 
intravenous administration of an undegradable sugar polymer: dextran, 
encapsulated in negatively charged liposomes. Both the free and 'the lipo-
somally encapsulated dextranase, subsequently administered, could degrade 
this accumulated substrate. Liposomally encapsulated dextranase was more 
effective than the free enzyme in degrading the accumulated substrate. This 
may be due to a more efficient delivery of dextranase into the cells by 
liposomes. 
To establish the effect of covalent modification of enzymes with 
hydrophilic polymers on their intracellular and intralysosomal stability, two 
enzymes horse radish peroxidase (HRP) and dextranase were chosen for 
study. HRP, a mannose-containing glycoprotein was chosen due to the ease 
of its detection. HRP is rapidly taken up by the liver and this uptake is 
markedly inhibited by mannan. After modification with dextran, HRP shows 
an enhanced half life in circulation and its uptake by the liver is consider-
ably reduced. This uptake is also inhibited by mannan although to a lower 
extent than that of the unmodified enzyme. The conjugate therefore partially 
retains its ligand property. This retention of ligand property even after 
modification is important when the ligand depends upon it for its action. 
Due to the different rates of uptake of the free and the modified 
enzyme by the liver, it was not possible to compare their intracellular stabil-
ity. Liposomes were therefore used as carriers for delivering the native and 
the modified enzyme to the liver at similar rates. The liposomally delivered 
dextran-HRP conjugate showed greater catalytic as well as immunological 
stability both intracellularly and intralysosomally compared to free HRP, 
free dextran-HRP and liposomally encapsulated HRP. Almost 40 % of the 
liposomally delivered dextran-HRP conjugate could be detected in the liver 
24 hours after administration compared to negligible amounts of the other 
formulations of HRP tested. 
To study the therapeutic efficacy of such modified enzymes in the 
treatment of a model storage condition, dextranase was modified with PEG. 
The enzyme lost all its activity upon conjugation. The conjugation procedure 
was therfore modified and the reaction was carried out in the presence of the 
substrate, dextran. 25-30% of the enzyme activity was recovered after 
conjugation. Interestingly, although PEG-dextranase shows enhanced half 
life in circulation, small amounts of the conjugate were taken up by the liver 
upon intravenous administration. 
Liposomes were used for delivery of the native and the modified 
enzyme to the liver at similar rates. Liposomally delivered PEG-dextranase 
conjugate showed enhanced intracellular and intralysosomal stability. The 
presence of dextranase inside the cell was monitored both by labeling with 
*^I and by assaying for catalytic activity. The liposomally delivered PEG-
dextranase was capable of both degrading the accumulated substrate as well 
as preventing its further accumulation over a period of time. Only negligi-
ble amounts of the other formulations of dextranase tested, namely free 
dextranase, free PEG-dextranase, and liposomally encapsulated ' • dex-
tranase could be detected in the liver 24 hours after administration. 
This enhanced stability of enzymes upon their extensive glycosyla-
tion with dextran or upon modification with PEG would be of importance in 
extending the catalytic life of therapeutically active enzymes. This would 
improve their therapeutic potential for the treatment of lysosomal enzyme 
deficiency disorders. 
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CHAPTER I 
INTRODUCTION 
AND 
REVIEW OF LITERATURE 
The potential of enzymes as therapeutic agents has long been consid-
ered. However, the use of enzymes as drugs was limited by their immuno-
genicity, short half life in circulation and rapid proteolytic degradation in 
vivo. In recent years a number of investigators have shown that it is possi-
ble to enhance the circulatory life of enzymes by their covalent modification 
with PEG or with dextran. Such conjugates also exhibit reduced immuno-
genicity. The therapeutic potential of the dextran-enzyme and PEG-enzyme 
conjugates is now well characterised. A number of enzyme conjugates such 
as PEG-adenosine deaminase and PEG-uricase have shown enhanced effica-
cy in curing disorders such as severe combined immunodeficiency and 
hyperuricemia respectively. Although the circulatory life of enzymes has 
been enhanced by this method, not much work has been done on the intrac-
ellular and intralysosomal stability of enzymes. 
Attempts made to use enzyme therapy in the treatment of lysosomal 
enzyme deficiency disorders have met with limited success only. Such 
disorders manifest themselves as storage conditions and the substrate of the 
deficient enzyme accumulates in the lysosomes of the affected cells. The 
main drawbacks in the treatment of enzyme deficiency disorders include 
delivery of the enzyme to the sites of substrate accumulation and the rapid 
intracellular degradation of the enzyme. 
Liposomes are ideal carriers for the delivery of enzymes, due to 
their biodegradability and their ability to deliver the entrapped enzyme to the 
lysosomes of the affected cells. The use of liposomes as an enzyme carrier 
was first suggested by Gregoriadis er a/ (1971). Liposomes can be target-
ted to different cell types by changing their composition, size, charge and by 
tailoring the liposomal surface with ligands specific for different receptors 
on different cell types. 
In this study we have tested the effect of modification of enzymes 
with PEG and dextran on their intracellular and intralysosomal stability. 
The efficacy of liposomally delivered enzyme conjugate in degrading the 
stored material in a model storage condition in mice and in preventing any 
further accumulafion of the substrate has also been studied. 
1.1 STORAGE DISORDERS 
A number of inherited metabolic disorders lead to the accumulation 
of metabolic intermediates due to the absence of some key enzyme responsi-
ble for their degradation. These disorders may be caused due to the defi-
ciency of either a cytosolic or a lysosomal enzyme. Here we will limit our 
discussion to lysosomal enzyme deficiency disorders only with particular 
reference to sphingolipidoses and a lysosomal glycogen storage disorder. 
1.1.1 Lysosomal sphingolipid storage disorders 
One of the first lysosomal enzyme deficiency in sphingolipidoses 
was reported from this laboratory in collaboration with Austin in 1963. 
They showed that metachromatic leukodystrophy was caused by the defi-
ciency of arylsulfatase - A which led to the accumulation of cerebroside-3' 
sulfate in the lysosomes. Cerebroside-3' sulfate was subsequently found to 
be the substrate for arylsulfatase - A (Mehl and Jatzkewitz,1965, Farooqui 
and Bachhawat,1973). Since then a number of enzymes are now known to 
be absent in a variety of sphingolipid storage disorders as shown in Fig 1, A 
variant form of metachromatic leukodystrophy is now known to be caused 
by the absence of a factor required for the hydrolysis of sulfatide even when 
the enzyme is active. 
One of the most prevalent sphingolipid storage disorders is 
Gaucher's disease which is caused by the deficiency of the enzyme B-gluco-
cerebrosidase. It results in the accumulafion of glucosylceramide in various 
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organs especially the liver and the spleen. Due to its prevalence, Gaucher's 
disease has been extensively studied. A naturally occuring canine model of 
Gaucher's disease has been reported but was not propagated (Hartley and 
Farrow, 1982). Attempts have also been made to mimic the disease in mice 
by inhibiting glucocerebrosidase (Kanfer et a/, 1982). More recently, 
Tybulesicz et al (1992) have generated an animal model for Gaucher's 
disease by creating a null allele in embryonic stem cells through gene target-
ting and using these genetically modified cells to establish a mouse strain 
carrying the mutation. Such mice have been shown to store glucocerebro-
side in lysosome of cells of the reticuloendothelial system. 
Fabry's disease is another sphingolipid metabolism disorder. It is 
caused by the deficiency of a-galactosidase. It was first noticed as pain in 
the joints especially when subjected to extremes of temperature. An ac-
cumulation of digalactosylceramide, which is present only in the kidney's of 
normal individuals, is found in almost all the organs and body fluids. 
Krabbe's disease is caused due to the deficiency of galactosylcera-
mide B-galactosidase (Suzuki and Suzuki, 1983) resulting in the accumula-
tion of galactosylceramide and galactosylsphingosine in the brain (Svenner-
holm et al, 1980). It causes mental retardation followed by death by the age 
of two. 
Another sphingolipid metabolic disorder Tay Sach's disease is 
caused due to the deficiency of B-hexosaminidase A. Early symptoms of 
this disease include a spot on the eye which causes blindness. It quickly pro-
gresses through motor retardation to a vegetative state. A variant form of 
Tay Sach's disease is caused even when the enzyme is active. Tay Sach's 
disease AB variant is caused due to the absence of a factor required for the 
hydrolysis of GM2 ganglioside. Table I lists a variety of sphingolipidoses 
and the nature of defect in each type of disorder. 
TABLE I 
DEFECTS IN LYSOSOMAL SPHINGOLIPID STORAGE DISORDERS 
(Tager, J.M. 1985) 
Disease Deficient hydrolase(s) Nature of Defects 
Tay-Sachs B-Hexosaminidase A 1. mRNA for ex-pre-
cursor absent 
2. Reduced synthe-
sis of a-precursor 
3. Insoluble a-pre-
cursor 
4. Labile a-precur-
sor 
5. Mature a-chain 
larger than 
normal and yields 
inactive enzyme 
6. Defective associa-
tion of a-precur-
sor with li-precur-
sor 
7. Reduced a-pre-
cursor synthesis 
and defective 
association with 
B-precursor 
Tay-Sachs 
disease 
B-Hexosaminidase 
activity with GM2 
ganglioside as 
substrate 
Absence of factor 
required for 
hydrolysis of 
GM2 ganglioside 
Metachromatic 
leukodystrophy 
Arylsulfatase A 
2. 
No precursor of 
arylsulfatase A 
formed 
Arylsulfatase A 
rapidly degraded 
in lysosomes 
Metachromatic 
leukodystrophy 
variant form 
Arylsulfatase A with 
sulfatide as substrate 
Absence of factor 
required for 
hydrolysis of 
sulfatiue 
Disease Deficient hydrolase(s) Nature of Defects 
Gaucher's 
disease 
B-Glucocerebrosidase B-Gluococerebro-
sidase with 
decreased stabi-
lity, enhanced 
degradation in 
lysosomes 
Mature B-galac-
tosidase reduced 
in amount and 
aggregates poorly 
The third column indicates the defects in synthesis, processing or stability of 
hydrolases, or other proteins, responsible for different forms of the diseases. 
The table omits a number of suspected lysosomal disorders whose bases are 
not yet well understood. 
As mentioned above, in some cases storage conditions are caused not 
only due to the deficiency of the enzyme but also due to the deficiency of 
some other lysosomal proteins which have non-enzymic roles, and function 
as activators or stabilizers of enzymes. Saposins constitute one such class of 
proteins, four of which are derived from a single precursor prosaposin by 
proteolytic processing. Saposins are small heat stable glycoproteins (12-14 
kDa) and are required for the lysosomal hydrolysis of a variety of sphingoli-
pids (Table II). 
Saposin B (previously known as sphingolipid activator protein-1) 
was found to activate the hydrolysis of cerebroside sulfate by arylsulfatase A 
and was later shown to activate the hydrolysis of GMl ganglioside by acid 
B-galactosidase and of globotriaosylceramide by a-galactosidase (reviewed 
by Li et al, 1988) Saposin B has a broad specificity and it acts as a detergent 
solubilizing multiple lipid substrates for enzyme hydrolysis. Deficiency of 
Saposin B results in tissue accumulation of cerebroside sulfate. The clinical 
picture resembles that of metachromatic leukodystrophy (Werger et al, 
1989). 
Saposin C (previously called sphingolipid activator protein 2) was 
discovered in 1971 by Ho and O'Brien (reviewed by O'Brien and Kishimo-
to, 1991), when it was shown to activate the hydrolysis of glucocerebroside 
by glucosylceramide fl-glucosidase. Later, the activation of hydrolysis of 
galactocerebroside B-gala'ctosidase by Saposin C was reported (reviewed by 
Glew et al, 1988). Saposin C raises the maximal velocity of these enzymes 
by as much as 10-fold (Radin, 1984). Saposin A was also found to stimulate 
the hydrolysis by the same enzymes, but to a lesser extent than Saposin C 
(Morimoto et al, 1989). Very little hydrolysis occured in the absence of 
Saposin A or C. The deficiency of Saposin C has been reported in a patient 
suffering from a variant form of Gaucher's disease (Christomanou et al, 
1986). 
TABLE n 
NOMENCLATURE AND FUNCTION OF SAPOSIN PROTEINS 
(from O'Brien and Kishimoto, 1991) 
Previous Names Enzyme Activated 
Saposin A 
Saposin B 
Saposin C 
SAP-1 
Salfatide/GM 1 -activator 
Dispersin 
Non-specific activator 
Factor P 
SAP2 
Coglucosidase 
A1-activator 
Heat Stable factor 
B-glucosylceramidase 
fi-galactosylceramidase 
Arylsulfatase A 
a-galactosidase A 
GM1 -li-galactosidase 
many others 
B-glucosylceramidase 
B-galactosylceramidase 
Saposin D Component C Sphingomyelinase 
Saposin D acts as a specific activator of sphingomyelinase activity 
with no effect on other lysosomal hydrolases (Morimoto et al, 1988). De-
tailed studies on kinetics have not been carried out, but in crude prepara-
tions it increases the rate of hydrolysis 3- to 5- fold. 
Another sphingolipid activator protein, known as the GM2 activator 
protein was shown to be a specific activator for the hydrolysis of ganglioside 
GM2 by fi-N-acetylgalactosaminidase (hexosaminidase A). This protein is 
genetically distinct from the saposin proteins, and its deficiency has been 
reported in a variant form of GM2 gangliosidosis (Conzelmann et al, 1978). 
1.1.2 Lysosomal glycogen storage disorder 
Pompe's disease or Type II glycogenosis is a glycogen storage 
disorder and is caused by the deficiency of lysosomal a-glucosidase. It 
results in the accumulation of glycogen in various organs especially the 
liver, spleen and the cardiac tissues. Although no animal models have been 
propagated to study this disorder, various investigators have tried to create 
artificial carbohydrate storage conditions both in vivo and in vitro. Expo-
sure to sucrose of mouse peritoneal macrophages (Cohn and Ehrenreich, 
1969) and Chinese hamster fibroblasts (Nyberg and Dingle, 1970) both 
lacking in invertase activity led to the accumulation of sucrose within their 
lysosomes. The lysosomes of these cells then appear as phaselucent va-
cuoles in the perinuclear region. Colley and Ryman (1976) created an in 
vivo model storage condition by intraperitoneal administration of dextran. It 
is known that intraperitoneal administration of dextran produces an increase 
in the density of liver lysosomes (Baudhuin et al, 1965). The artificial 
storage conditions were very useful for developing various therapeutic 
approaches for the treatment of such disorders. Animals which have been 
made deficient in an enzyme in order to mimic a naturally occuring storage 
condition do not survive long enough for any therapeutic approaches to be 
tried. 
1.2 THERAPEUTIC APPROACHES : 
1.2.1 Genetic engineering 
A number of approaches have been tried to cure storage disorders. 
These include genetic engineering. The idea was to introduce the gene of 
the deficient enzyme and express it inside the cell in order to alleviate the 
disorder. 
Nontargetted delivery of genes into cells can be accomplished by 
chemical or physical means (transfection). In this approach many copies of 
the DNA carrying the healthy gene are mixed with a charged substance 
typically calcium phosphate, DEAE-dextran or certain lipids. When ex-
posed to these chemicals, the cell membrane is disturbed and the DNA is 
transported into the cell interior (Sabrook et al, 1989). Although the proce-
dure is simple, the efficiency of gene delivery is only 1 in 1000 to 100,000 
and this reduces its clinical potential. 
Physical methods such as microinjection are very efficient, but are 
tedious as only one cell can be injected at a time. Electroporation or expo-
sure of cell to electric shock although efficient, can severely damage the 
cell. 
A number of investigators have suggested retroviruses as vectors 
(Hamer and Leder, 1979, Mulligan et al, 1979). Retroviruses, however are 
not without drawbacks. They can merge only with the cells capable of 
actively dividing. Most cells, such as mature neurons, do not divide and are 
not readily amenable to being genetically altered. The cancer causing ability 
of retroviruses is another drawback. 
Fraley et al (1979) recognised the potential of liposomes for gene 
transfer and showed that it is possible to entrap a bacterial plasmid into 
liposomes. Subsequently they introduced liposomally encapsulated SV40 
DNA into plant protoplasts (Fraley et al, 1980). Expression in the host cell 
of liposome entrapped DNA was later observed by a number of investiga-
tors. Wong et al (1980) demonstrated the appearance of B-lactamase activ-
ity in animal cells. Nicolou and Rottem (1982) showed the expression of 
fi-Iactamase activity in mycoplasma, and Schaefer-Ridder et al (1982) 
showed efficient transformation of mouse L cells by thymidine kinase gene. 
Encouraged by the promising potential of liposomes for gene deliv-
ery, several people attempted to improve the delivery by exploiting the 
knowledge of targetting to different receptors. Stavridis et al (1986) used 
transferin grafted liposomes for in vivo delivery of DNA to bone marrow 
erythroblasts in rabbits. pH- sensitive immunoliposomes have been used to 
deliver liposomal DNA to the cell cytoplasm (Wang and Huang, 1989). 
Recently, Legendre and Szoka (1992)showed that cationic liposomes are 
superior to pH-sensitive liposomes for delivery of plasmid DNA into 
mammalian cell lines. After delivery into the cells, DNA should reach the 
nucleus for expression. Working towards this goal, Kaneda et al (1989) 
encapsulated human insulin gene in liposomes containing gangliosides and 
incubated these liposomes with RBC membranes containing non-histone 
chromosomal protein (HMGl). The vesicles were cointemalised with 
HMGl and transported to the liver nucleus, where the gene was expressed. 
The amount of human insulin in rat serum gradually increased to a maxi-
mum after 7-8 days and then decreased rapidly. The therapy was therefore 
short lived. 
Two groups (LeMeur et al, 1985, Yamamura et al, 1985) almost 
simultaneously treated mice incapable of producing antibodies when exposed 
to certain synthetic molecules. The deficiency was due to the alteration of a 
certain gene belonging to the histocompatibility complex (known as H-2 in 
mice). They injected the cloned gene into the embryos of deficient mice. 
The resulting mice appeared to be completely cured and were capable of 
producing antibodies. 
The first clinical trial of gene therapy for genetic diseases was 
conducted at NIH, (for review Verma, 1990), where H.Blaese, W.F. 
Anderson and their colleagues introduced the gene for the enzyme adenosine 
deaminase into children suffering from severe combined immunodeficiency 
disorder. 
Although great strides have been made in the expression of exogene-
ous genetic material in animals, however genetic engineering is still in its 
infancy. The various drawbacks of gene therapy include the difficulty in 
controlling the fate of DNA inside the cell. For every gene spliced in the 
correct place, more than 1000 fit randomly into the genome. The other 
problems to gene therapy include the ethical question of whether gene thera-
py should be limited to somatic cells or also be applied in the germ cells. 
Will gene therapy in germ line cells be tampering with human evolution? 
Till questions such as these can be discussed and answered it would be safer 
to think of gene therapy in somatic cells only. 
1.2.2 Organ transplant 
Another approach has been organ transplant as in the case of Fabry's 
disease. An accumulation of digalactosylglucosylceramide was seen in 
almost all organs and body fluids of patients suffering from this disorder. 
Digalactosylceramide is found only in the kidneys of normal individuals 
were a-galactosidase cleaves the non-reducing terminal galactose residues 
of the trisaccharide group. The absence of a-galactosidase from the kidney 
leads to the accumulation of the trisaccharide. Transplantation of a normal 
kidney in such patients has shown considerable success in alleviating the 
disorder (Clarke et al, 1972). 
1.2.3 Enzyme replacement therapy 
The therapeutic approach to storage disorders which has received the 
most serious consideration is the possibility of replacing the missing en-
zyme. This approach is based on the premise that the lysosomal apparatus 
of the cell can take up the glycoprotein enzymes from the extracellular fluid 
by means of receptor mediated endocytosis. Most of the lysosomal hydrola-
ses are glycoproteins. The cell surface is known to express a number of 
sugar specific receptors, such as the galactose specific receptors on hepato-
cytes, (Ashwell and Morell, 1974) and the mannose receptors on kupffer 
cells (Stahl et a/, 1978). Several experimental models have been presented 
to support this idea. Cohn and Ehrenreich (1969) showed that cultured 
mouse peritoneal macrophage vacuoles distended by a sucrose load were 
normalised upon addition of invertase. 
Human trials of enzyme replacement therapy were also conducted in 
a number of patients . Di Ferrante et al (1971) and Erickson, et al (1972) 
treated patients suffering from Hunter's syndrome with normal plasma. 
Plasma contains the expected normal enzyme, and as such serves as its 
source. Plasma infusion, however, met with limited success as the concen-
tration of the missing enzyme is very low and even large quantities of 
plasma were not sufficient. It must also be pointed out that such patients 
often suffer from defective cardiovascular apparatus and therefore cannot be 
subjected to regular plasma infusions (Schieken et aly 1975). 
In another trial normal leukocytes were infused in a patient suffering 
from Hunter's disease. Such patients are deficient in leukocyte iduronate-
sulfate sulfatase (Knudson, 1971). No long term improvement was observed 
in the clinical or biochemical manifestations of the disease. There was 
however a short term improvement in the a-L-iduronidase levels and a 
clinical improvement in the stiffness of joints. 
The reversal of storage disorders has also been approached by means 
of direct enzyme replacement. Several trials have been performed with 
purified enzymes from human sources. Sly et al (1973) described the first 
patient suffering from mucopolysaccharidosis type VII. Such patients are 
deficient in B-glucuronidase and they do not degrade sulfated mucopolysac-
charides. Clinical symptoms include urinary excretion of elevated amounts 
of chondroitis 4-sulfate, hepato-splenomegaly and skeletal abnormalities. In 
1974, Sly et al treated the patient with highly purified B-glucuronidase 
from human thrombocytes. In another trial Johnson et al (1973) intra-
venously administered purified hexosaminidase-A into a patient suffering 
from Tay-Sachs disease in order to mobilise the GM2-ganglioside stores. 
Both these investigators met with limited success only, due to the rapid 
removal of the enzyme from the circulation and its accumulation in the 
liver. The uptake of the enzyme by the liver limited its therapeutic efficacy 
in this case as liver was not the only organ involved in the storage of the 
substrate. 
It was gradually realised that enzyme therapy is hampered by many 
drawbacks which must be overcome before such a therapy can become 
viable. They include a) adverse immunological reactions against the admin-
istered enzyme and b) removal and intracellular degradation of the intra-
venously administered enzyme by the RES, which may limit the exposure 
time of the enzyme to the accumulated substrate. 
1.3 LIPOSOME AS AN ENZYME CARRIER 
In the search for an appropriate carrier for therapeutically active 
enzymes and proteins it was felt that the various problems of enzyme thera-
py might be circumvented by the entrapment of enzymes in liposomes. 
Liposomes are biodegradable lipid vesicles with concentric lipid 
bilayers alternating with aqueous compartments. Water soluble substances 
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like enzymes can be entrapped in these aqueous compartments. Liposomes 
were first described by Bangham and coworkers in 1963 and by 1968 Sessa 
and Weissmann had coined the term "liposome" for them. 
Over the years, various methods of liposome preparation have been 
perfected and newer methods developed. They have been comprehensively 
reviewed by Szoka and Papahadjopoulos (1980). Depending upon their 
shape and size, liposomes can be classified into three types namely multila-
mellar, small unilamellar and large unilamellar (Fig. 2). Multilamellar 
vesicles are spontaneously formed upon hydration of the phospholipid film. 
They are made up of a number of lipid bilayers surrounding the aqueous 
compartments. SUVs and LUVs are made up of just one bilayer enclosing 
one aqueous compartment. They differ from each other only in size. 
Liposomes can be formed from many different phospholipids, and 
the composition most commonly used is egg phoshatidylcholine, with or 
without cholesterol and with or without anionic lipids such as phosphatidic 
acid and cationic lipid such as stearylamine. The distance between the 
bilayers in MLVs is determined by a balance between the repulsive forces 
(mainly electrostatic interactions between headgroups and hydration forces 
of the head groups) and by the attractive Van der Waal's forces (LeNeveu et 
al, 1976). It is possible to increase this distance and thus the aqueous phase 
entrapped by the addition of upto 10 mol% of charged lipid (either cationic 
or anionic) into the phospholipid (Bangham et al, 1967). 
Liposomes and other particulate ligands are more avidly taken up by 
the reticuloendothelial cells in the liver and the spleen due to the sinusoidal 
(discontinous) epithelia of the capillaries. The endothelia of these vessels 
has gaps upto 100-200 nm in diameter (Motta and Makable, 1980). This 
epithelia allows small particulate substances to pass through the vasculature 
into the surrounding tissue. Most other organs possess the continuous epi-
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thelia which does not allow liposomes to pass through it. The multilamellar 
liposomes are taken up by cells of the RES, lining the sinusoids in the liver 
and spleen. Juliano and Stamp (1975) have shown that MLVs are taken up 
by the RES more rapidly than the SUVs. It was also observed that the 
negatively charged liposomes were taken up by the liver more rapidly than 
the positively charged or neutral liposomes (Gregoriadis and Neerunjun, 
1974). 
Gregoriadis and Ryman (1972) have shown that the activity of an 
enzyme in liposomes remains latent while they are in circulation and much 
of the enzyme activity is recovered from the hepatic lysosomes indicating 
that the liposomally encapsulated enzyme is protected from the environment. 
There are many advantages in the use of liposomes as enzyme carri-
ers. They include avoidance of the presence of a foreign protein in the 
circulation, the lack of immunological response and the possibility of direct-
ing the enzyme carrier to a particular tissue by changing the lipid composi-
tion, size, charge etc. It is also possible to tailor the liposomal surface to 
target them to the diseased tissue. 
1.3.1 Cell-specific targetting of liposomes 
In a systematic approach to the problem of designing liposomes that 
would bypass the RES, Surolia et al (1975) set up a very simple liposome 
model system to study the receptor-ligand interaction. A 2-fold increase in 
the GMl concentration, for example, led to a 20-fold increase in the rate of 
interaction with the lectin. Further, it was observed that the phase transition 
temperture of the phospholipid component of liposomes, the length of the 
surface-bound oligosaccharide chain and cholesterol concentration also 
affect the binding of the terminal sugar with the lectin (Surolia and Bachha-
wat, 1978). 
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In a series of decisive experiments, Ashwell and Morell (1974) 
characterised a receptor specific for 6-gal containing glycoproteins on 
hepatocytes. Surolia and Bachhawat (1977) then started their studies on in 
vivo targetting to the hepatocytes using galactosylated liposomes. They 
observed that following intravenous administration, upto 45% of the admin-
istered liposomes containing GMl ganglioside accumulated rapidly (within 
15 minutes) in the liver by a 6-gal specific receptor mediated pathway. 
Later Ghosh and Bachhawat (1980) showed that intravenously 
administered liposomes containing asialo GMl ganglioside, accumulated in 
the liver. This accumulation was dependent on the density of the galactose 
residues on the liposomal surface, and was inhibited by competition with 
asialofetuin. It was observed that B-gal liposomes preferentially accumulat-
ed in the hepatocytes as compared to a-gal liposomes (Ghosh et al, 1981) 
indicating that the hepatic receptors are specific for B-gal containing li-
posomes. When the livers of mice previously administered aGMl li-
posomes were perfused, the hepatocytes were found to be three times more 
efficient than the nonparenchymal cells in taking up these liposomes (Ghosh 
et al, 1982, Dasgupta and Bachhawat 1985). These observations that uptake 
of liposomes by hepatocytes is galactose dependent were subsequently con-
firmed by a number of other laboratories (Spanger and Scherphof 1983, 
Szoka and Mayhew 1983, Gregoriadis and Senior 1984). 
A variety of other targetting ligands have also been used for this 
purpose. Weissmann and Coworkers (1977) have shown that liposomes 
coated with aggregated IgG provide a far better endocytic stimulus than the 
uncoated liposomes. Aggregated rather than native immunoglobulins pref-
erentially coat and partially insert into liposomes forming lattices in which 
key Fc regions are exposed on the surface of the liposomes. These Fc 
regions act as ligands for Fc receptors of the polymorphonuclear leukocytes 
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(PMN) and consequently provoke endocytosis. Uptake of HRP encapsulated 
in aggregated IgM coated liposomes exceeded that of the free enzyme by 
120 fold, native IgM coated liposomes by 60-fold and uncoated liposomes 
by 50-fold (Weissmann et al, 1975). It has been shown that hexosaminidase 
A is taken up more actively when presented to Tay-Sach*s phagocytes as 
aggregated IgG liposomes, than when presented in liposomes coated with 
native IgG or in uncoated liposomes (Cohen et al, 1976). 
1.3.2 Long circulating liposomes 
a) Modification of liposomal surface with dextran 
One important prerequisite to efficient targetting of liposomes is to 
prevent their uptake by the RES and to enhance their circulatory life, so that 
they can interact with other cell types also. Pain et al (1984) showed that it 
was possible to do so by conjugating cyanogen bromide-activated dextran 
(mol wt 70,000) on the surface of PE containing liposomes. The dextran-
coated liposomes were more efficient in retaining the entrapped radioactive 
compounds in circulation, and the concentration of these liposomes in the 
circulation 2 h after administration was found to be two fold higher than that 
of uncoated control liposomes. Other investigators have also used polysac-
charides to enhance the in vivo stability of liposomes and for bypassing the 
RES (Sunamoto, 1986). 
b) Modification of liposomal surface with GMl ganglioside 
Allen and Chonn (1987) showed that it was possible to enhance the 
circulatory life of liposomes by incorporating GMl ganglioside into the 
liposomes composed of PC and Choi. GMl acts synergistically with Choi 
in stabilising the liposomes (Allen et al, 1985). It not only reduces the 
susceptibility of liposomes to lysis by blood components but also enhances 
the circulatory levels 3- to 10-fold. Incorporation of Sphingomyelin (SM) 
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into PC liposomes at a 1:1 molar ratio led to a dramatic increase in the 
levels of circulating liposomes with a concomitant decrease in uptake by the 
liver and the spleen. The levels of SM:PC liposomes in RES at optimal 
GMl ganglioside concentrations (7-15 mol%) were > 25-fold lower than 
those observed for PC:Chol liposomes of comparable size. Allen et al 
(1991) have shown that compounds such as GMl, SM and Choi, which 
reduce the uptake of liposomes in vivo also led to a decrease in their uptake 
by bone marrow macrophages in vitro. 
Gabizon and Papahadjopoulas (1988) have also shown that there is 
an increase in the blood residence time, with a concomitant decrease in the 
uptake by liver and spleen, for liposomes composed of certain glycolipids in 
combination with solid phase phospholipids and cholesterol. 
GMl:DSPC:Chol liposomes elicited the longest circulatory life followed by 
DPPG:DSPC:Chol, GMl:PC:Chol and DPPG:DSPC:Chol liposomes, in 
that order. They have also observed a strong correlation between the resi-
dence time of liposomes in blood and their uptake by tumors implanted in 
mice. GMl:DSPC:Chol liposomes showed a 25-fold increase in the lipo-
somal concentration in the tumors and there was a 20-fold increase in the 
tumor to body ratio, indicating that the accumulation of liposomes was 
preferentially enhanced in the tumors as compared to the rest of the body 
tissues. 
GMl has also been used for prolonging the residence time of pH-
sensitive liposomes in the circulation. This is particularly relevant as the 
pH- sensitive liposomes are known to provide an efficient delivery system in 
in vitro studies. However, pH-sensitive liposomes have not been used 
successfully in animals due to their high susceptibility to degradation by 
plasma proteins, accompanied by their rapid uptake by the RES. Liu and 
Huang (1989) have shown that pH- sensitive liposomes composed of dio-
leoylphosphatidyl ethanolamine and dipalmitoyl succinylglycerol retain 40-
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50% of their pH-sensitivity in the presence of 5% GMl. These liposomes 
were found to be more resistant to the destabilising influence of plasma 
components and elicited a longer residence time in circulation. This makes 
pH-sensitive liposomes potentially useful drug carriers in vivo. 
Recently Maruyama et al (1990) using a model system, have empha-
sised that the long life span of liposomes in the circulation constitutes an 
essential factor for optimal binding of immunoliposomes to the target cells. 
GMl coated immunoliposomes have a long life span in circulation and thus 
offer a potentially useful delivery system for defined targets. 
c) Modification of the liposomal surface with PEG 
Although GMl ganglioside was very successful in prolonging the 
ciculatory life of liposomes, however its potential use in the clinics is 
severely limited by its high cost. Therefore, a search for a cheaper substi-
tute was started. Klibanov et al (1990) in an attempt to design liposomes 
with a long life span in the circulation and reduced affinity towards RES, 
modified the liposomal surface by including a lipophilic derivative of PEG, 
prepared by coupling activated PEG with PE. They observed that PEG 
liposomes were highly stable and retained 90% of the entrapped fluorescent 
markers in the presence of human serum over a period of 24 h. The ability 
of PEG-PE to enhance the circulatory life of liposomes was striking. The 
half life of liposomal clearance from blood was <0.5, 0.5, 1.5 and 5h for 
liposomes made up of PCrChol, PC:Chol:PEG-stearyl ester, PC:Chol:GMl 
and PC:Chol:PEG-PE respectively. 
Blume and Cevc (1990) reported that liposomes coated with PEG-
5000 were removed from the blood at only 15% of the rate characteristic of 
DSPC liposomes. Even 8 h after injection, the level of PEG-coated li-
posomes in the circulation was higher than that in the liver. Allen et al 
(1991) have reported a substantial reduction in the uptake of PEG-PE con-
taining liposomes by the bone marrow macrophages in vitro, 
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Senior et al (1991) studied the interactions of monomethoxy poly-
ethylene glycol (mPEG)-coated liposomes with plasma by an aqueous two-
phase partitioning technique, and then compared these interactions with 
those obtained for control, i.e. uncoated liposomes. They observed that the 
distribution of control liposomes in the two-phase partitioning system was 
rapidly altered with most of the liposomes moving towards the lower phase 
within 1 minute after incubation with serum. This distribution was similar to 
that of the plasma itself, indicating that there is some association between 
the plasma proteins and the liposomal surface. mPEG-coated liposomes, on 
the other hand, take a much longer time (up to 6 h) to move towards the 
lower phase. The PEG- coated liposomes, therefore, interact slowly with 
the plasma proteins in vitro, which may be partly responsible for an increase 
in their circulatory life in vivo. Senior et al (1991) have also reported a 
30% slower removal of these liposomes from the circulation compared to 
control liposomes. They further observed that when the serum components 
associated with the liposomes are removed by gel filtration, mPEG li-
posomes once again partition as in the absence of serum, indicating that the 
movement towards the lower phase is not due to the loss of PEG. 
The exact mechanism whereby PEG prevents the interaction of 
opsonins and other serum proteins with liposomes is not known. This may 
due to a restructuring of water molecules around PEG, which leads to steric 
exclusion of macromolecules, particularly proteins, from regions of water 
occupied by the inert PEG (Atha and Ingham, 1981). Blume and Cevc 
(1990) have calculated the thickness of the surface region inaccessible to 
water-soluble proteins to be " 2 nm for DSPC liposomes containing 10% 
DSPE-PEG. PEG chains anchored in a phospholipid may also accentuate 
repulsion between opposing bilayers (Arnold et al, 1986), thereby prevent-
ing excessive aggregation of liposomes and their uptake by the RES. A 
similar mechanism may be responsible for the enhanced half life of 
dextran/PEG modified enzymes in circulation. 
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The ability of liposomes to protect the entrapped enzyme from 
adverse immunological reactions and to target it to the diseased tissue made 
them very important tools for enzyme therapy. The efficacy of liposomes in 
delivering the entrapped enzyme has been studied extensively both in vitro 
and in in vivo models. 
1.3.3 Use of liposomes in enzyme therapy 
Gregoriadis and Buckland (1973) exposed Chinese hamster fibro-
blasts to sucrose. Due to the absence of invertase, there was an accumula-
tion of sucrose in the lysosomes of these cells. Subsequent exposure of 
these cells to liposomally encapsulated invertase led to the degradation of the 
stored sucrose indicating that invertase was incorporated into these cells. In 
another study Colley and Ryman (1976) developed a model storage disorder 
in rat liver by intraperitoneal administration of dextran. It is known that 
intraperitoneally administered dextran accumulates in the liver lysosomes 
thereby increasing their density (Baudhuin et al, 1965). In the absence of 
the enzyme dextranase, dextran is not degraded in mice. However, admin-
istration of liposomal dextranase lead to the degradation of the stored mate-
rial. Interestingly even the free enzyme was able to reverse the storage 
condition in these experiments. Although the amount of free dextranase 
taken up by the liver was found to be considerably less than when it was 
entrapped in liposomes, it was still enough to degrade all the stored dextran. 
This study did not show any enhanced efficacy of liposomal dextranase over 
the free enzyme, due to the small amounts of dextran loaded into the liver 
and the relatively large amounts of dextranase administered. It however, 
does serve to show that enzyme entrapped in liposomes can be taken up the 
liver and released in an active form capable of degrading the stored materi-
al. 
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A number of human trials have also been conducted to test the effic-
acy of liposomally encapsulated enzyme in the treatment of storage condi-
tions. The first was conducted by Tyrrell, Ryman and coworkers in 1976. 
A four month old female child with hypotonia, generalised weakness, 
hepatomegaly and cardiomegaly was diagnosed to be suffering from Pom-
pe's disease caused by the lack of lysosomal a-glucosidase. At eight months 
the child was treated with liposomes (composition; PC:Chol:DCP, 7:2:1) 
containing amyloglucosidase for seven days. Though the liver decreased 
markedly in size during the first four days of treatment, there was no 
improvement in the heart condition and the child died eight days after the 
commencement of therapy. In the postmortem tissues examined, only trace 
amounts of the enzyme could be detected in the liver which was not surpris-
ing as most would have been catabolised by the liver cathepsins. The 
glycogen levels in the muscle and the cardiac tissues were found to be very 
high. However, those in the liver were lower than expected in a patient 
suffering from Pompe's disease. The lower levels of glycogen in the liver 
can be explained, as the liposomes of the composition mentioned would be 
taken up most avidly by the liver and therefore degrade the material stored 
there. 
In another study, a 25 year old woman suffering from Gaucher's 
disease was treated with liposomal 6-glucosidase for five years by Gregoria-
dis and co-workers (1980, 1982). The lack of B-glucosidase lead to a rise of 
the glucocerebroside levels particularly in the cells of the RES. The enzyme 
deficiency was clinically manifested by the enlargement of the liver and 
spleen and by bone deformations. After five years of treatment, the patient 
showed a stabilisation of the clinical condition, an improvement in the func-
tion of the RES and absence of toxic effects upon chronic administration of 
liposomes. Due to the absence of any other patient suffering from 
Gaucher's disease, it was not possible to compare the efficacy of liposomal 
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enzyme therapy in the patient with an untreated control. It is therefore not 
possible to conclusively say that the stabilization of the patients condition 
was due to the therapy given. 
A number of investigators have shown that although liposomally 
entrapped enzymes could be selectively delivered to the liver lysosomes, but 
once there they are very rapidly catabolised (Gregoriadis and Neerunjun, 
1974). The rapid degradation of the administered enzyme severely limits its 
therapeutic potential and thereby the efficacy of enzyme therapy in control-
ling such disorders. Work therefore started in several laboratories to find 
ways of enhancing the stability of the administered enzyme in the ly-
sosomes. These efforts such as cross-linking of liposome entrapped proteins 
with glutaraldehyde met with limited success (Gregoriadis and Neerunjun, 
1974). In order to successfully improve the stability of the administered 
enzyme in the lysosomes, it is first important to understand the nature of 
lysosomal hydrolases. These enzymes, despite being proteinacious in nature 
are remarkably stable in the acidic milieu of the lysosomes (Pazur 
and Aronson, 1972, Pazur et aU 1970). Some properties of these en-
zymes are common such as (a) an acid pH optimum, (b) resistance to 
autolysis, and (c) their glycoprotein nature. The glycoprotein nature of the 
lysosomal hydrolases and their resistance to autolysis was very intriguing. 
Saraswathi and Bachhawat (1970) showed that removal of the terminal sialic 
acid of the enzyme alkaline phosphatase does not impair its catalytic activi-
ty. However, removal of the terminal sugar lead to a markedly reduced 
survival time in circulation indicating that it had a role to play in the in vivo 
circulatory life of the enzyme (Baynes and Wold, 1976). Realising the 
importance of carbohydrates in the in vivo survival of proteins, Bachhawat 
suggested that it might be possible to prolong the in vivo survival of en-
zymes by their covalent modification with polysaccharides (1973). 
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1.4 EFFECT OF COVALENT MODIHCATION OF ENZYMES WITH 
POLYETHYLENE GLYCOL AND DEXTRAN 
Various approaches have been used to enhance the in vivo stability of 
enzymes and proteins. One of the more successful approches has been to 
link proteins to non-immunogenic hydrophilic polymers. Compounds that 
are to be used for conjugating pharmacologically - active proteins and 
peptides must be able to form stable conjugates, should remain in the circu-
lation for long periods of time and must have low immunogenicity and 
antigenicity. The two major hydroxyl group containing polymers, polyethy-
lene glycol (PEG), and dextran possess all these qualifications. PEG is a 
linear, uncharged, non-immunogenic compound with the general struc-
ture HO-(CH2-CH2)n-OH. It is compatible with blood and is available in 
various molecular weight ranges. The two hydroxyl groups, which are 
available for modification caused cross-linking of the conjugates. To over-
come this complication, a monofunctional derivative of PEG, monomethoxy 
PEG (mPEG) is used. 
Dextran is an inert polymer of D-glucose units linked predominantly 
a-D (1 -> 6) and is compatible with blood. 
1.4.1 Methods of coi\jugation 
The most common methods of coupling such hydroxyl group con-
taining polymers depend upon the activation of the hydroxyl groups, which 
are otherwise not sufficiently reactive to form covalent bonds between the 
polymer and enzyme. Most approaches for the activation involve the intro-
duction of an electrophilic group into the polymer to make it more reactive 
towards the nucleophiles present in the enzyme. This is followed by cou-
pling with the nucleophilic moieties present on the proteins. The linking 
reactions should be carried out under conditions that are mild enough to 
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ensure the chemical integrity of even the most labile enzyme. The method 
of conjugation to be used should be chosen carefully, so as to result in the 
minimum loss of activity of the proteins or enzyme molecules. 
The E-amino groups of lysine and the N-terminal amino groups of 
the proteins are most commonly used for coupling them to the activated 
hydroxyl groups of PEG or dextran. Sometimes the carboxylic groups on 
proteins are also used for coupling. Some of the more commonly used 
methods for coupling PEG and dextran to proteins include : 
a) CNBr activation 
Fig.3a shows that CNBr reacts with the hydroxyl groups of dextran 
at alkaline pH (10-12) to produce derivatised matrices that react readily with 
the amino groups on proteins (Axen et aly 1967). Although the use of 
triethylamine instead of NaOH for maintaining the pH results in extremely 
high coupling, this method also suffers from several disadvantages. The N-
substituted isourea derivatives formed are not completely stable particularly 
in the presence of other nucleophiles. Another disadvantage is the high 
toxicity of CNBr. 
b) Carbonyldimidazole activation 
PEG and dextran may be activated using carbonylating agents such 
as N,N-carbonyldiimidazole and the coupling efficiency achieved by this 
method is comparable to that of CNBr (Fig. 3b). This method also results 
in the formation of peptide-like bonds (Hearn et al, 1981). This reagent is 
less toxic and the degree of modification can be controlled by the extent of 
activation of dextran or PEG. The conjugates obtained by this method are 
extremely stable. 
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c) Oxirane-based reactions 
Bis-oxiranes such as 1, 4-butanediol diglycidoxy ether react readily 
at alkaline pH with hydroxy or amino containing matrix to yield derivatives 
which possess a long chain hydrophilic reactive oxirane (Fig. 3c). The 
oxirane-coupled conjugates are extremely stable and are used widely. Other 
bifunctional reagents that may be used for attachment of proteins to PEG 
and dextran include divinylsulphone (Porath et al, 1975) and organic sul-
phonyl chlorides (Nilson and Mosbach, 1984). 
d) 2,4,6-TrichIoro-s-triazine (cyanuric chloride) 
Cyanuric chloride reacts with amino, imino and hydroxy! groups to 
form stable linkages (Fig. 3d). The first chlorine reacts readily at 4°C, the 
second at 25® and the third at 80*^ C in aqueous solutions at pH 9.0. 
e) Periodate method of oxidation 
Periodate oxidation leads to the formation of a Schiff s base linkage 
between the carbonyl groups on dextran and the free amino groups on the 
protein (Fig. 3e). This method depends on the oxidation of the cis-vicinal 
hydroxyl groups of dextran by sodium metaperiodate (NalO^) to generate 
aldehydic functions. The dialdehydes react at a pH between 4 and 6 with 
primary amines to form Schiff bases, which can be reduced by either NaBH^ 
(sodium borohydride) or NaBH^ CN (sodium cyanoborohydride) to form 
stable secondary amines. This is a very rapid, simple and safe method 
which results in the formation of chemically stable dextran-protein bonds, 
1.4.2 Circulatory life of the enzyme cor\jugates 
Upon covalent modification with dextran (Table Ilia) or with PEG 
(Table Illb), enzymes exhibit enhanced half lives in circulation. Various 
factors have been evoked to account for this increase in the circulatory life. 
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TABLE Ilia. 
CIRCULATORY HALF LIFE OF DEXTRAN-ENZYME CONJUGATES 
Enzyme 
Carboxy-
peptidase 
Uricase 
Asparaginase 
Catalase 
Half life 
of Enzyme 
3.1 h 
0.6 h 
11 h 
0.3 h 
Half life 
of conjugate 
45.6 h 
7.5 h 
190 h 
2.5 h 
References 
Melton et al 
(1987) 
Yasuda et al 
(1990) 
Benbough et al 
(1979) 
Marshall et al 
(1977) 
TABLE Illb 
CIRCULATORY HALF LIVES OF PEG-ENZYME CONJUGATES 
Enzyme 
Superoxide 
dismutase 
(SOD) 
Adenine 
deaminase 
(ADA) 
L-Asparaginase 
Uricase 
Lactoferrin 
Half life 
of Enzyme 
0.05 h 
0.5 h 
20 h 
0.6 h 
0.05 h 
Half life 
of conjugate 
16.5 h 
28 h 
357 h 
6.6 h 
1.0 h 
References 
Beauchapm 
etal 
(1983) 
Davis 
etal 
(1981) 
Ho et al 
(1986) 
Yasuda 
etal (\990) 
Beauchamp 
etal 
(1983) 
These include steric surface barriers created by PEG or dextran residues 
attached to the protein. These barriers prevent or reduce the recognition of 
enzyme with specific receptors on the surface of certain cells. Further, 
uptake of molecules by the RES is thought to be mediated by some as yet 
unidentified serum components called "opsonins" (Moghini and Patel, 
1989). Opsonins bind to the hydrophobic regions of the molecules. The 
presence of PEG or dextran makes the enzyme surface hydrophilc which 
may prevent any interaction with opsonins. 
Enhanced circulatory life of enzyme conjugates has also been attrib-
uted to the decreased clearance by glomerular filtration by the kidney 
(Beuchamp et al, 1983). Knauf et al (1988) showed that recombinant inter-
leukin-2 (rIL-2) and some PEG-rIL2 conjugates upto 70 KDa had serum 
clearance values predicted for small molecular weight proteins by glomeru-
lar filtration (Maack et al, 1979, Venkatachalam and Rennke, 1978). The 
larger the PEG-rIL2 conjugate, slower was the rate of its clearance by 
kidney due to its progressive exclusion from glomerular filtration. 
In vitro studies have shown that the modified proteins exhibit en-
hanced resistance to proteolytic degradation. A number of studies have 
described the enhanced stability of dextran or PEG-enzyme conjugates to 
proteolysis. While trypsin is auto digested within 2 hours, the dextran-
trypsin conjugate shows no degradation during the same time period 
(Marshall and Rabinowitz, 1976). Other enzymes conjugates like PEG-
catalase (Abuchowski et al, 1977), dextran- carboxypeptidase Gj (Melton et 
al, 1987), PEG-uricase and dextran-uricase (Yasuda et al, 1990) also show 
enhanced resistance to degradation not only by trypsin but also by chymo-
trypsin and protease from streptomyces grigeus. The resistance to trypsin 
may be expected as the substrate amino acids of trypsin namely lysine and 
arginine are involved in conjugation with PEG and dextran. The reason for 
enhanced stability against degradation by chymotrypsin is less clear. It may 
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be due to a steric barrier formed by PEG or dextran to the approaching 
proteolytic enzyme. Enhanced resistance to proteolytic degradation may 
also be a contributing factor to the increased circulatory life. In this regard 
it is interesting to note that PEG-gluconolactone oxidase which is not pro-
tected from proteolytic cleavage by trypsin in vitro, does not show any 
increase in its half-life in circulation (Hadley and Sato, 1989). Such modi-
fied enzymes are increasingly finding clinical use in the treatment of various 
deficiency disorders. 
1.4.3 Immunogenicity of the cor\jugates 
A large body of work done by various investigators suggests that 
covalent modification of enzymes with PEG or with dextran renders the 
protein incapable of elliciting antibodies against itself (Table IV). The 
freedom from antigenicity is particularly important in the event where re-
treatment with the enzyme is required at frequent intervals. Streptokinase, 
for example, is a strongly antigenic bacterial protein. It has the property of 
clot lysis by activation of the fibrinolytic system of the human blood (Ei-
narsson et al, 1979) and its clinical effects have been tried in the treatment 
of thrombosis. However, the greatest disadvantage associated with the 
treatment with streptokinase is its antigenicity. Koide et al (1982) have 
shown that it possible to produce a non-immunogenic streptokinase by its 
modification with PEG under controlled conditions. The degree of modifi-
cation of streptokinase determined its therapeutic potential. Modification of 
8 amino groups resulted in conjugates that showed no binding against its 
antibody and retained 33% of the streptokinase activity. However, modifi-
cation of 12 amino groups showed no binding against its antibody, but it 
also resulted in a complete loss of streptokinase activity. 
Lee and Sehon (1977,1978) have shown that coupling of certain 
allergens to PEG yields conjugates which are non-immunogenic and are 
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TABLE IV 
IMMUNOGENICITY AND ANTIGENICITY OF ENZYME MODIFIED 
WITH PEG OR DEXTRAN 
Conjugate 
PEG-BSA 
PEG-calalase 
PEG-rIL2 
Dextran-
Uricase 
PEG-aenosine 
deaminase 
PEG-arginase 
PEG-
Streptokinase 
Immune reaction 
of conjugate with 
antibody raised 
against free 
enzyme 
No interaction 
No interaction 
-
Interacts weakly 
No interaction 
No interaction 
No interaction 
Immunogeni-
city of 
conjugate 
No immune 
response 
No immune 
response 
Weak litres 
of only IgM 
antibodies 
Very weak 
immune 
response 
No immune 
response 
No immune 
response 
No immune 
response 
References 
Abuchowsk 
era/, 1977 
Abuchowski 
etal, 1977 
Katre 
etal, 1990 
Yasuda 
etal, 1990 
Davis 
etah\n\ 
Savoca 
etal, 1979 
Koide et al 
1982 
capable of suppressing in an immunologically specific manner, the capacity 
of animals to mount primary as well as secondary response to sensitising 
doses of DNP-ovalbumin. To establish the cellular mechanisms underlying 
the suppression by conjugates, the spleen cells of the tolerised mice as well 
as their splenic T and B subpopulations were transferred into normal syn-
genic recipients. They were immunised subsequently with a sensitising dose 
of DNP-ovalbumin, and it was observed that while the splenic B cells of 
tolerised donors did not possess any suppressive capacity The unfractionat-
ed spleen cell population as well as the T cells of immunosuppressed mice 
undermined the capacity of normal recipients vigorous anti-OA responses. 
It was, therefore concluded that the immune suppression was primarily if 
not exclusively due to the activation of T suppressor cells (Lee et al, 1981). 
The activation of T-helper cells to most soluble antigens occurs only 
if the antigen is processed by macrophages and presented to the T cell 
membrane in association with the appropriate gene product encoded by 
MHC-I. In contrast, processing of the antigen by the macrophages does not 
seem to be necessary for the activation of T-suppressor cells. In fact, the 
very opposite appears to be the case (Takatsu and Ishizaka, 1977; Skidmore 
and Katz, 1977). It therefore appears that the immuno-suppressive capacity 
of these conjugates is probably due to their resistance to processing by the 
macrophages. 
Although the PEG or dextran conjugates of enzymes were non-
immunogenic in almost all cases, however only in a few cases were they 
able to suppress in a specific manner the capacity of animals to mount 
immunological responses to sensitising doses of the unmodified antigen. 
Savoca et al (1979) have shown that though arginase modified with PEG 
was rendered both non- immunogenic and non-antigenic, PEG-arginase did 
not induce tolerance towards the native enzyme . Similarly, mice injected 
with PEG-catalase remained immune competent for native catalase 
(Abuchowski et al, 1977). 
1.4.4 Intracellular stability 
Although enhanced stability, prolonged life span, reduced immuno-
genicity and therapeutic efficacy have been demonstrated by a number of 
investigators, not much work has been done on stabilising enzymes intracel-
lularly with particular reference to the lysosomes. Blomhoff et al (1983) 
have shown that B-galactosidase is markedly stabilised against degradation 
in isolated parenchymal and nonparenchymal cells in vitro after its conjuga-
tion with dextran. Compared to the native enzyme, degradation was found 
to be reduced by 35% in the parenchymal and by 43% in the nonparenchy-
mal cells after 80 and 40 minutes of incubation respectively. In another 
study Melton et al (1987) showed that carboxypeptidase-G2 is stabilised 
upon modification with dextran. Once again the study was limited to radiol-
abelling experiments which gave no idea as to the catalytic integrity of the 
enzyme. The apparent stabilisation of the dextran-CPG2 conjugate in this 
case may also be due to gradual uptake of the conjugate from the circulation 
rather than its stability inside the cell. Dextran-CPG 2 conjugate had an 
extended half life in circulation. No carriers for the intracellular delivery 
of the enzyme and the conjugate were used, and the uptake of the two by the 
cells was dissimilar. These studies were based on the presence of the radi-
olabelled enzyme inside the cell and no attempt was made to study the cata-
lytic and immunological integrity of the enzyme inside the cell. Hence, from 
these experiments it was not possible to evaluate the intracellular functional 
integrity of the enzyme. 
1.4.5 Therapeutic efficacy of PEG and dextran coi\jugates 
Covalent attachment of PEG or dextran to immunogenic proteins is a 
general method for reducing, modifying or eliminating the immunogenicity 
of proteins. It, therefore, finds many applications in immunology and medi-
cine. Human Interleukin-2 (IL-2), obtained from genetically engineered 
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E,coli as an unglycosylated recombinant protein (rIL-2) has therapeutic 
potential in treating cancers. However, both the native IL-2 and the geneti-
cally engineered rIL-2 are rapidly cleared from the circulation in mice and 
rats resulting in limited bioavailability of the protein. Katre et al (1987) 
suggested that increasing the bioavailability of rIL-2 could increase its 
potency, thus facilitating a more effective use of this protein as a drug. 
They showed that conjugation with PEG enhanced the solubility of rIL-2, 
decreased its plasma clearance, and was 60 times more potent than rIL-2 in 
curing Meth A murine sarcoma in mice. 
The possibility of the use of hemoglobin solutions as a blood substi-
tute has long been considered. Studies on the use of stroma-free hemoglobin 
as a blood substitute have advanced as far as the stage of clinical trials. 
However, due to its relatively small size, hemoglobin infused into the circu-
lation is rapidly eliminated through the kidney and other metabolic routes, 
severely limiting its utility. Tam et al (1976) have suggested the use of a 
soluble dextran- hemoglobin conjugate as a potential blood substitute. They 
showed that the dextran-hemoglobin conjugate could bind and release 
oxygen reversibly, and also had a much longer circulating life. It, there-
fore, increased the functional life span of hemoglobin. 
A number of clinical trials have been conducted with PEG-modified 
enzymes. Davis et al (1981) showed that the circulatory life of adenine 
deaminase was enhanced 56 times upon its modification with PEG. Hersh-
field et al (1987) treated two children suffering from severe combined 
immunodeficiency disease caused by adenosine deaminase deficiency with 
bovine adenosine deaminase conjugated to PEG. They observed that the 
principal biochemical consequences of adenosine deaminase deficiency were 
almost completely reversed. The clinical improvement was indicated by the 
absence of infection and resumption of weight gain. In another clinical trial, 
a patient suffering from hyperuricemia was treated with PEG-modified 
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uricase (Chua et al, 1988). A dose of 2 U/kg body weight every 5 to 6 days 
was enough to reduce and maintain the plasma urate level at 540 ^mole/liter 
or even lower. Other studies on enzyme deficiency disorders also showed 
the increased efficacy of enzyme-PEG conjugates in the treatment of such 
disorders. Lee and Sehon (1977) showed the increased efficacy of PEG 
conjugates in the treatment of certain allergenic reactions. 
The underlying reason for this enhanced therapeutic efficacy is the 
reduced immunogenicity of the PEG and dextran conjugates compared to 
that of the free enzyme and their longer circulatory lives. This increases the 
bioavailability of the enzyme, thereby giving it a better chance to do its job. 
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AIMS AND OBJECTIVES 
The use of enzymes for the treatment of enzyme deficiency disorders 
has been suggested by a number of investigators. The therapeutic role of 
enzymes is however limited by a) Immunological response against the 
administered enzyme, preventing its repeated administration, b) dilution of 
the enzyme in circulation, so that the amount reaching the sites of substrate 
accumulation is not sufficient, and c) rapid degradation of the enzyme in 
lysosomes, which are often the sites of substrate accumulation. 
Various investigators therefore decided to use liposomes as carriers 
of the encapsulated enzymes for the treatment of storage disorders. In vivo 
studies showed that encapsulation into liposomes prevented dilution of the 
enzyme in circulation and fecilitated delivery of the encapsulated enzyme to 
the sites of substrate accumulation. Liposomal encapsulation also prevented 
an immunological response against the administered enzyme, thereby 
making repeated administration possible. Several clinical trails were also 
conducted for the treatment of a lysosomal glycogen storage disorder 
"Pompe's disease" using liposomally encapsulated enzyme 6-glucosidase. 
Although it was possible to destroy the stored substrate using liposomally 
encapsulated enzyme, the therapeutic effects of the enzyme were short lived 
due to its degradation in the lysosomes. 
Further investigations therefore needed to be carried out to enhance 
the intracellular particularly the intralysosomal stability of the enzyme in 
order to reduce the frequency of its administration thereby making enzyme 
therapy a viable option. With this in view we approached the problem of 
making intracellularly stable enzymes. 
A number of in vitro studies had earlier shown that modification of 
enzymes with PEG or with dextran enhances the thermal stability of the 
enzyme and reduces its susceptibility to degradation by trypsin, chymotryp-
30 
sin etc. Work has also been carried out to show that such modified enzymes 
have a much longer circulatory life than the unmodified enzyme. Long 
circulating enzymes such as PEG- adenosine deaminase and PEG-uricase 
have also been used successfully in clinical trials. 
Although enzymes have been shown to be stabilized in vitro, and 
their circulatory life enhanced in vivo, not much work has been done on 
their intracellular stability particularly intralysosomal stability. Intralyso-
somal stability is very important as lysosomes are not only the sites of sub-
strate accumulation in lysosomal storage disorders they are also bags of 
hydrolytic enzymes which would rapidly degrade the therapeutic enzymes. 
Blomhoff et al did study intracellular stability of B-galactosidase and 
they found a marked stabilisation of the enzyme against degradation in iso-
lated parenchymal and nonparenchymal cells, after its modificaton with 
dextran. Their studies were however all based upon the presence of the 
radiolabelled enzyme inside the cell and they made no attempt to study the 
functional integrity of the enzyme. Although this study served as a pointer, 
it did not explore the ability of the enzyme in degrading the accumulated 
substrate or preventing its further accumulation. In another study Melton et 
al showed that carboxypeptidase G2 is stabilised upon modification with 
dextran. Their conclusions were also based upon the presence of the radio-
active marker in vivo. The apparent stabilisation of dextan-CPG2 conjugate 
in this case may also be due to gradual uptake from the circulation rather 
than actual stabilisation. Both these studies did not show any enhanced 
stability to denaturation in the acidic milieu of the lysosomes. 
With this in view we have approached the problem of modifying 
enzymes so that their stability inside the cell is enhanced, and delivering 
them to the macrophage lysosomes. Macrophages are the sites of substrate 
accumulation in a number of lysosomal enzyme deficiency disorders. It is 
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known that multilamellar vesicles are rapidly removed from the circulation 
by the macrophages. MLV*s were therefore used as carriers of enzymes 
throughout the study. Two enzymes, horse radish peroxidase and dextranase 
were chosen for the study. HRP was used as a model enzyme due to the 
ease of its detection. It was modified with dextran and the effect of this 
modification on its circulatory life, intracellular and intralysosomal stability 
was studied. Liposomes were used as carriers for delivering the native and 
the modified HRP inside the cell. Next, dextranase was modified with PEG 
and the effect of modification with PEG and encapsulation into liposomes on 
the stability of the enzyme was studied. The ability of various formulations 
of dextranase in degrading the stored substrate in a model storage disorder 
and in preventing further accumulation of the substrate was also examined. 
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CHAPTER II 
2.1 INTRODUCTION 
Despite its great potential, the success of enzyme replacement thera-
py in the treatment of lysosomal storage disorders has been limited. Though 
most of the problems associated with enzyme therapy such as immunogenici-
ty of the administered enzyme, dilution in circulation and targeting to the 
site of substrate accumulation have been wholly or partially conquered. The 
problem that still remains to be solved is the intracellular instability of the 
administered enzyme. Once the enzyme reaches the lysosomes which are 
often the sites of substrate accumulation, it is rapidly degraded by the lyso-
somal hydrolases. This reduces the therapeutic life of the enzyme and neces-
sitates its frequent administration. 
As discussed earlier, enzymes have been shown to be stabilised in 
vitro (Marshall and Rabinowitz, 1976, Abuchowski et al, 1977) and their 
circulatory life enhanced in vivo (Melton et al, 1987, Yasuda et al, 1990) by 
modification with hydrophilic polymers such as PEG and dextran. Such 
modified enzymes exhibit enhanced resistance to degradation by trypsin and 
chymotrypsin in vitro. However, similar in vitro studies on the stability of 
conjugates to degradation by lysosomal acid hydrolases have not been per-
formed. 
Blomhoff et al (1983) have shown enhanced stability of B-galactosi-
dase after its modificaton with dextran in isolated parenchymal and kupffer 
cells in vitro. Similarly, Melton et al (1987) have shown that 3.1% of 
radiolabeled carboxypeptidase G2 - dextran conjugate injected is still present 
in the liver 48 hours after administration, compared to only 0.03% of the 
unmodified carboxypeptidase 02 administered indicating enhanced intracel-
lular stability of the modified enzyme. Interestingly carboxypeptidase G2 
when administered intravenously shows no tissue uptake by the liver. On 
modification with dextran, however, small amounts (= 11%) of the enzyme 
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accumulate in the liver within six hours. Dextran acts as a carrier of car-
boxypeptidase G2 for delivery to the liver. 
Although enhanced intracellular stability of enzymes after modifica-
tion with dextran has been demonstrated, this study nevertheless leaves 
several questions unanswered. First, as the free enzyme is not taken up by 
the liver, the relative stability of the native and the modified enzyme cannot 
be compared. Secondly, the persistance of the conjugate in the liver may be 
due to gradual uptake of the dextran-enzyme conjugate from the circulation 
and not due to reduced degradation. Another important point is that both in 
this study and the tissue study conducted by Blomhoff et al (1983) a radio-
active label Q'^ I) has been used as a marker for studying the presence of 
the enzyme inside the cell. These results do not give any indication as to the 
catalytic properties of the enzyme: about whether the enzyme is present in 
the catalytically active form, partially degraded or denatured form inside the 
cell particularly in the acidic milieu of lysosomes. 
All these results, as well as the fact that most of the lysosomal 
hydrolases are glycoproteins and are extremely stable in the lysosomes 
(Pazur and Aronson, 1972) suggested that carbohydrates have a role to play 
in the stabilization of enzymes intracellularly and intralysosomally. 
To investigate this possibility, we decided to extensively modify an 
enzyme with a nondegradable soluble polysaccharide. Due to the ease of its 
detection, horse radish peroxidase (HRP), a terminal mannose containing 
glycoprotein (Welinder, 1979) was chosen, as a model enzyme for this 
study. We decided to covalently modify it with dextran, an inert polymer of 
D-glucose units linked predominantly a-D(l-6). Dextran is not degraded in 
mice (Mowry and Millican, 1953). It is biocompatible and is frequently used 
as a plasma expander in medicine. 
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HRP has been used extensively as a nonspecific macromolecular 
tracer due to the ease of detection by both biochemical and cytochemical 
methods. It was considered to be a marker for fluid phase pinocytosis exclu-
sively in macrophages (Steinman and Cohn, 1972., Steinman et al , 1976). 
More recently in vitro work on mouse peritoneal and rabbit alveolar mac-
rophages indicates that these cells endocytose HRP both by fluid phase 
and by receptor mediated uptake (Stahl and Gordon, 1982, Stahl et al, 
1978). Lang and Chastellier (1985) have shown that the rate of uptake of 
HRP, by bone marrow macrophages in culture, is multiphasic. With HRP 
conncentrations higher than 100 /ig/ml the intracellular uptake of HRP was 
linear with marker concentration which is characteristic of fluid phase 
pinocytosis. Below 100 /ig/ml the uptake of HRP was disproportionately 
high indicating another mechanism of uptake. To check if mannose receptor 
was involved in the uptake of HRP, mannan was added to the culture prior 
to the addition of HRP. There was a marked inhibition of uptake and 
this inhibition increased with increasing concentrations of HRP till a 
maximum of 100 /xg/ml. Above that it once again became linear with con-
centration, indicating the involvement of a mannose specific receptor in the 
uptake of HRP at concentrations below 100 /xg/ml. They have also shown 
that at a concentration of 1000 /ig HRP/ml, 80% of HRP is taken up by 
fluid phase and 20% by receptor-mediated endocytosis. The converse is 
observed when the medium contains only 25 ^g HRP/ml. 
Studies on formalin fixed frozen sections of liver have also shown 
that HRP is bound to receptors specific for mannose groups of glycoproteins 
(Straus, 1981). 
Rodman et al (1978) have shown that blood clearance of HRP is 
inhibited by mannan and by the periodate oxidation of its sugar residues 
indicating that HRP is cleared by specific recognition, and that the sugar 
residues on the enzyme act as recognition determinants which mediate rapid 
plasma clearance. 
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In view of the in vitro reports that HRP binds to and is taken up by 
the mannose receptor and the in vivo reports that HRP is cleared from circu-
lation by specific recognition, probably via the mannose receptors, we 
decided to investigate the in vivo uptake of HRP by the liver. 
It is known that the kupffer cells of the liver express mannose spe-
cific receptors (Schlesinger et al, 1978, Achord et at, 1978). The presence 
of mannnose specific receptors on the surface of macrophages was first 
reported by Stahl et al in 1978. The physiological role of this receptor is 
the regulation of extracellular levels of lysosomal hydrolases (Steinman, 
1983, Shepherd et al, 1984). It is a 175kD protein which binds ligands 
with terminal mannose or N- acetylglucosamine (Shepherd et al, 1981). It 
has been isolated from a variety of species including humans, rat and rabbit 
(Stephenson and Shepherd, 1987, Wileman et aU 1986, Haltiwanger and 
Hill, 1986). 
The mannose receptor is an example of a recycling receptor (Stahl et 
a/, 1980). The affinity of ligands for the mannose receptor is pH dependent, 
and the binding of radiolabeled mannan has been shown to be maximal at 
pH 7.5 in the presence of Ca^^. Wileman et al (1985) have shown that after 
internalisation, the receptor-ligand complex undergoes dissociation in the 
acidic compartment of the endosomes. This dissociation requires ATP, 
possibly to power endosomal acidification via an ATP- dependent proton 
pump. Having been dissociated from the ligand, the receptor recycles back 
to the cell surface (Stahl et al, 1980, Tietz et al, 1982). 
The presence of mannose receptor on the cell surface is closely 
regulated. It is not present on the surface of circulating monocytes and is 
poorly expressed on bone marrow cells in the early stages of macrophage 
differentiation (Shepherd et al, 1982). Glucocorticoids can regulate the 
expression of mannose receptors. During inflammation, macophages infil-
trate such areas and secrete lysosomal hydrolases into the extracellular 
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spaces (Schnyder and Baggioline,1980). Glucocorticoids, such as dexam-
ethasone, which are extensively used as anti-inflammatory agents increase 
the expression of this receptor (Shepherd et al, 1985) and thus reduce in-
flammation. 
In this section we report the mechanism of HRP uptake by the liver 
and the effect of modification of the enzyme with dextran on its uptake. 
The effect of extensive modification of HRP with dextran on its intracellular 
and intralysosomal stability has been studied. Negatively charged MLVs 
have been used as carriers of HRP and dextran-HRP conjugate for delivery 
to the liver lysosomes. Such negatively charged MLVs can entrap a larger 
aqueous phase (Bangham et al, 1967) and they are taken up by the liver 
more rapidly than the neutral or positively charged liposomes (Gregoriadis 
and Neerunjun, 1974). 
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MATERIALS AND METHODS 
2.2 MATERIALS 
Dextran (av. mol wt. = 40,000) from leuconostoc mesenteroides, 
mannan from Saccharomyces cerevisiae, horse raddish peroxidase (EC 
1.11.1.7) type VI A, specific activity 1280 units/ mg protein, anti horse 
raddish peroxidase antibody, bovine serum albumin, o-phenylene diamine, 
cholesterol and dicetylphosphate were purchased from Sigma Chemical Co. 
St. Louis, MO, USA. Egg phosphatidyl choline (EPC) was purchased from 
Nippon Oil and Fat Co. Ltd., Hyogo, Japan and Bio gel P- 200 was pur-
chased from Bio Rad Laboratories, USA. ELISA fast binder, PETG coated 
assay plates were obtained from Costar, USA. All other chemicals used 
were also of analytical grade. 
Animals Male Swiss albino mice (20-25gms) were purchased from All India 
Institute of Medical Sciences, Delhi. 
2.3 METHODS 
2.3.1 Preparation of dextran-HRP conjugate 
Dextran-HRP conjugate was prepared following the method de-
scribed by Marshall and Rabinowitz (1976). In brief, the pH of a stirred 
solution of 200 mg dextran in 30 ml distilled water was adjusted to 10.8 
with NaOH and 50 mg CNBr was added to it. The pH was maintained at 
10.8 for the next 30 minutes with vigorous stirring. 50 mg CNBr was added 
once again, and kept for another 30 minutes at pH 10.8 with vigorous stir-
ring. The temperature was maintained at 4°C. 
Thirty minutes after the second addition of CNBr the solution was 
dialysed at 4*'C for two hours, against two liters of sodium carbonate solu-
tion pH,9.0, with two changes of buffer. 
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The pH of the solution was adjusted at 9.0 and 8 mg HRP was added 
to this dialysed solution of activated dextran. Coupling of HRP to CNBr 
activated dextran was allowed to proceed for 15 hours at 4°C. The residual 
activated groups on dextran were blocked by reaction with 2.4 ml of 100 
mg/ml glycine solution for five hours. The conjugate was then dialysed 
against sodium carbonate solution pH, 9.0 for 2 hours and lyophilised 
2.3.2 Purification of dextran-HRP coiyugate 
3 ml PBS containing 100 mg dextran-HRP conjugate was loaded on 
a Bio gel P-200 column (2 X 90 cms), equilibrated with 0.01 M phosphate 
buffer, pH, 6.0. 2.5 ml fractions were collected in the same buffer at a 
flow rate of 20 ml/hour. The fractions were analysed for enzyme activity 
(Worthington, 1988) and carbohydrate content (Du Bois et al, 1956). A 
control was also run, in which equivalent amounts of dextran and HRP were 
mixed and chromatographed on the same column. 
2.3.3 Enzyme assay for HRP 
HRP was assayed according to the method described in Worthi-
ngtons Catalogue (Worthington, 1988). Briefly, the substrate was prepared 
by adding 833 /xl of o-dianisidine (1% solution in Methanol) and 1 ml of 
H2O2 (diluted 100 times with H^O) to 98 ml of phosphate buffer (0.01 M, 
pH 6.0). 
For assay 2.95 ml substrate was taken in a glass cuvette, and 50 /il 
of appropriately diluted enzyme added to it. The change in absorbance was 
monitored at 460nm. The blank was adjusted by taking 2.95 ml substrate in 
a cuvette and adding 50 ml of phosphate buffer to it. 
2.3.4 Carbohydrate estimation 
Dextran was assayed by the method described by Du Bois et al 
(1956). The volume of 1(X) /il of the sample to be estimated was made upto 
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2 ml, and 1 ml of 5% phenol added to it. The reaction mixture was mixed 
well by vortexing and 5ml of concentrated U^SO^ added to it. The tubes 
were cooled in an ice bucket and the straw colour developed was read at 
490 nm in a LKB spectrophotometer. 
2.3.5 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis of 
dextran-HRP coi^ugate 
SDS-polyacrylamide gel electrophoresis was carried out in vertical 
slab gels according to the method of Laemmli et al (1973). To 10 /xl of 
HRP or purified dextran-HRP conjugate containing 5 ^g protein, an equal 
volume of sample buffer was added giving a final concentration of 2% (w/v) 
SDS, 125 mM Tris-HCl (pH 6.8) and 10% (v/v) glycerol with a trace of 
bromophenol blue as a tracking dye. The sample was loaded on a 10% 
seperating gel with a 3% stacking gel. The running buffer for electrophore-
sis was made up of 0.05 M Tris, 0.0112 M glycine and 0.1% SDS (pH 
8.5). After the run, gel was stained for 30 minutes a solution containing 
40% methanol, 10% acetic acid and 0.05% coomassie brilliant blue R-250. 
The gel was destained overnight in destaining solution containing 11 % 
methanol and 7% acetic acid in water. 
The mobility of dextran-HRP conjugate was compared with that of 
HRP. 
2.3.6 Km Values for HRP and for dextran-HRP coi\jugate 
To determine the Km value of HRP and dextran-HRP conjugate, 
enzyme activity was measured spectrophoto- metrically (Worthington, 
1988). The concentration of o-dianisidine was kept constant and the rate of 
reaction was measured at varying concentrations (25-1000 /iM) of H2O2. 
Km values were determined by calculating the slope of the Eadie-Hofstee 
plots constructed. 
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2.3.7 Preparation of liposomes containing HRP or dextran-HRP con-jugate 
Liposomes were prepared with EPC, cholesterol and dice-
tylphosphate in the molar ratio of 7:2:2 according to the method of Surolia 
et al (1975). In short, the lipids (20 mg) were dissolved in a 2:1 mixture of 
chloroform-methanol and a thin dry film of the lipids was made on the sides 
of a round bottom flask by rotary evaporation at 37**C under reduced pres-
sure. The film was hydrated with 1 ml PBS (phosphate buffer, pH 7.4 con-
taining 0.15M NaCl) containing either 5(X) /xg of HRP or HRP conjugated 
with dextran. The dispersion was completed by brief sonication (30 sec-
onds) in an MSE ultrasonicaton The unentrapped HRP or dextran-HRP 
conjugate was separated by repeated washings in PBS by ultracentrifugation 
at 105,000 X g for 30 minutes. 
ANIMAL EXPERIMENTS 
2.3.8 Uptake and stability of free or liposomally encapsulated HRP and 
dextran-HRP in the liver 
Male Swiss albino mice weighing approximately 25-30 gms were 
used throughout the study. Each mouse was given a single intravenous 
injection of 0.2 ml PBS containing 2.5 /ig HRP either free or conjugated 
with dextran. In another set of experiments 0.2 ml liposomes containing 2.5 
/ig HRP, either free or conjugated with dextran were injected. Three 
animals from each set were sacrificed after 30 min, 1 hr, 6 hr and 24 hrs. 
2.3.9 Effect of dextran on the uptake by the liver 
To study if dextran itself had any effect on the uptake of free HRP 
and HRP conjugated with dextran, a control experiment was conducted in 
which 0.2 ml PBS containing either 2.5 /xg HRP plus 1 mg dextran or 2.5 
ng HRP conjugated with dextran plus 1 mg dextran were injected intra-
venously. Three animals each were sacrificed from both sets after 30 
minutes. 
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2.3.10 Competition studies with mannan 
To study the effect of mannan on the uptake of HRP and dextran-
HRP conjugate, 0.2 ml PBS containing 1.6 mg mannan was injected via the 
tail vein of mice, followed 10 min later by an injection of 0.2 mi PBS 
containing 2.5 fig HRP either free or conjugated with dextran. Three ani-
mals from each set were sacrificed 30 minutes after the second injection. 
In all cases, after sacrificing the animals, blood was drawn from the 
heart and the liver removed. Blood was clotted and centrifiiged to give 
serum, 
2.3.11 Subcellular fractionation 
Livers were washed in saline, blotted, weighed and homogenised in 
PBS. The homogenate was subsequently fractionated by differential cen-
trifugation into nuclear, mitochondrial/lysosomal and soluble fractions 
(Gregoriadis and Sourkes, 1967). Briefly, the volume of the homogenate 
was made up to 10 ml. One ml was kept aside for estimation of the total 
HRP in the liver. The rest was centriftiged at 1000 x g for 15 minutes. The 
pellet containing nuclei, unbroken cell and cell debrie was discarded and 
the supernatant was centriftiged at 12000 x g for 30 minutes. Volume of the 
pellet containing the mitochondrial/lysosomal fraction was made upto 5 ml. 
Supernatant containing the microsomal and soluble fractions was discarded. 
2.3.12 ELISA 
HRP in tissues was assayed by the enzyme linked immunosorbent 
assay system (ELISA). All the solutions for the assay were prepared in 
ELISA buffer (PBS containing ImM CaC12 and MgC12). The homogenate 
and the mitochondrial/lysosomal fractions were frozen and thawed before 
being assayed. 
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In short, ELISA plates were coated with 1:6000 times diluted anti-
HRP antibodies and left overnight at 4*^ C. The non specific binding sites 
were blocked for one hour with 3% BSA. Excess BSA was removed by 
washing with ELISA buffer. Appropriately diluted tissue samples were 
added and incubated for an hour at room temperature. Excess tissue sam-
ples were removed by washing with ELISA buffer. The HRP present in the 
tissues, and thus bound to the plates was directly assayed for enzyme activi-
ty. 100 /il substrate was added to the plates. The enzyme-substrate reaction 
was quenched 5 minutes later with 30 ul of 5N HjSO^. The yellow colour 
was monitored at 460 nm in a virion ELISA reader. 
The substrate for HRP was made up of 5 mg o-phenylenediamine 
and 10 /il of 30% H2O2 in 100 ml citrate phosphate buffer containing 
0.025M citric acid and 0.05 M Na2HP04, pH 5.0. 
Liposomally entrapped HRP was also assayed in a similar way after 
treating the liposomes with 0.01% Triton X-100. Binding with its antibody 
does not affect the enzyme activity of HRP, as the antibody is specific for 
the carbohydrate moieties on HRP (Kurosaka et al, 1991). ELISA is a very 
sensitive assay system and even 0.5 ng of HRP could be detected by this 
method. The intrinsic peroxidase present in the tissue does not cross react 
with the anti-HRP antibody and therefore does not interfere in the assay. 
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2.4 RESULTS AND DISCUSSION 
2.4.1 Preparation and characterisation of the dextran- HRP coi^jugate 
Fig,la gives the gel filteration profile of the conjugate on a Bio-gel P 
200 column. The conjugated enzyme eluted in the void volume of the 
column associated v i^th dextran. Fractions 20-26 were pooled, lyophilised 
and used for all further experiments with the dextran-HRP conjugate. The 
unconjugated enzyme eluted as a seperate peak. In controls, where equival-
ent amounts of HRP and dextran were mixed and loaded on the same 
column, the two components eluted as seperate peaks. It was thus conclud-
ed that HRP was covalently attached to dextran, and it is the conjugate 
which eluted in the void volume. 
Further evidence of the covalent attachment of HRP to dextran, with 
the formation of a high molecular weight conjugate came from the compari-
son of their mobility on SDS polyacrylamide gel electrophoresis (Fig lb). 
While the native enzyme migrated as a single band of expected molecular 
weight (40,000), the conjugate showed of broad diffused band of glycopro-
tein at the top of the gel, indicating that it was of a high molecular weight. 
Only 20% of the enzyme activity of HRP was lost during conjuga-
tion. After gel Alteration 3 mmoles of HRP were found to be bound per 
mole of dextran. The Km values obtained by the Eadie-Hofstee plot for 
HRP and dextran-HRP conjugate were almost similar for H2O2 indicating no 
change in the affinity for the substrate (Fig 2). 
2.4.2 Circulatory life of HRP and dextran-HRP conjugate 
When HRP, either free or conjugated with dextran, was adminis-
tered intravenously into mice it was observed that the free enzyme is cleared 
very rapidly from the circulation and only negligible amounts of the injected 
dose could be detected 30 minutes after administration. However, almost 
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FIGURE la 
GEL nLTRATION PROFILE OF DEXTRAN ( • ) AND HRP ( V ) 
AFTER CONJUGATION ON A BIO-GEL P200 COLUMN. 
Arrows la and 1 mark the elution position of native HRP. Arrow 2 marks 
the elution position of native dextran. Enzyme activity of HRP was assayed 
by monitoring the change in absorbance at 460 nm. Dextran was assayed at 
490nm. 
FIGURE lb. 
SDS PAGE ANALYSIS OF THE NATIVE HRP (LANE A) AND THE 
DEXTRAN-HRP CONJUGATE (LANE B). 
HRP and dextran-HRP were subjected to a 10% SDS-Page in the absence of 
reducing agent, and the gel was stained with Coomassie Blue. 
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DETERMINATION OF Km VALUES FOR HRP AND DEXTRAN-
HRP CONJUGATE. 
The concentration of o-dianisidine was kept constant and the rate of reaction 
was monitored at varying concentrations (25-1000 /xM) of H2O2. Km values 
were calculated from the slope of the Eadie Hofstee plots. 
65% of the injected dextran-HRP conjugate could be detected in the circula-
tion 30 minutes after administration and 48% could be detected one hour 
after administration (Fig. 3). These results are not very surprising, as 
various investigators have shown that the circulatory life of proteins and 
enzymes is significantly increased upon conjugation with dextran or with 
polyethylene glycol (Melton et al, 1987, Yasuda et al, 1990). 
When HRP or dextran-HRP conjugate were encapsulated into li-
posomes and administered, not much difference was observed in the circu-
lating levels of the free or conjugated enzyme. About 20% of liposomally 
encapsulated enzyme, free or conjugated with dextran, could be detected in 
circulation one hour after administration. After six hours only negligible 
amounts could be detected. The enhanced circulatory life of dextran-HRP 
conjugate may be due to the dextran coating. Carbohydrate coating has 
been suggested to be responsible for preserving a water shield around the 
protein (Blomhoff and Christensen, 1983), thus making the surface of the 
protein hydrophilic. Phagocytosis by the RES is mediated by opsonins which 
prefer to associate with hydrophobic surfaces. Making the surface hydrophi-
lic would therefore be expected to reduce the uptake by the RES (Van Oss et 
aly 1975, Ilium and Davis, 1986). The enhanced hydrophilicity and the 
reduced uptake by the RES maybe responsible for the longer circulatory life 
of dextran-HRP conjugate. 
2.4.3 Uptake of HRP and dextran-HRP coi\iugate by the liver 
About 40% of the intravenously administered HRP was found to 
accumulate in the liver in 30 minutes. Prior administration of mannan, 
which competes for binding with the mannose receptors on the kupffer cells, 
markedly inhibited this uptake by the liver and the serum levels of the 
enzyme were found to be elevated. On the other hand only 13% of the 
injected dextran-HRP conjugate was taken up by the liver in 30 minutes. 
This uptake was also inhibited by mannan, though to a lower extent (Table 
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FIGURES 
CIRCULATORY LIFE OF HRP ( v ),DEXTRAN"HRP ( • ) , LIPO-
SOMALLY ENCAPSULATED HRP (o) and DEXTRAN-HRP (•) . 
2.5 \i,% of HRP, free or conjugated with dextran either before or after encap-
sulation into liposomes was injected i.v.into three swiss albino mice in each 
group. Animals were sacrificed after various intervals of time. Blood was 
drawn from the heart and the presence of HRP assayed by ELISA. Data is 
expressed as percentage of HRP administered ±_ SD. 
TABLE I 
EFFECT OF MANNAN ON THE UPTAKE OF HRP AND 
DEXTRAN-HRP CONJUGATE BY THE LIVER 
Experiment % of the Administered dose 
Serum Liver 
HRP 
HRP + Mannan 
HRP-dextran 
conjugate 
HRP-dextran 
conjugate -f Mannan 
6 ± 2 
69 ± 26 
69 ± 4 
41 ± 2 
7 ± 2 
13+2 
90 ± 4 8 + 2 
L6 mg mannan was injected i.v. into three Swiss albino mice in each group. 
This was followed 10 minutes later by an injection of 2.5 ^g HRP, either 
free or conjugated with dextran. Animals were sacrificed after 30 minutes 
and HRP was assayed in the serum and liver by ELISA. Each value is 
expressed as pecentage of the administered dose ± S.D. 
I). 8% of the dextran-HRP conjugate administered was taken up by the 
liver even in the presence of mannan. This uptake may be due to the carri-
er effect of dextran. Melton et al (1987) have shown that while carboxypep-
tidase G2 is not taken up at all after intravenous administration, however 
upon conjugation with dextran, 8-10% of it is taken up by the liver. Dex-
tran therefore functions as a carrier for carboxypeptidase G2 for its uptake 
into the liver. 
The accumulation of HRP in the liver and the subsequent inhibition 
of uptake by mannan indicates that HRP is taken up by liver by the mannose 
receptor mediated pathway. The dextran-HRP conjugate also seems to be 
taken up by the same pathway as indicated by the mannan inhibition experi-
ments. Conjugation with dextran, however, leads to a considerable reduc-
tion in the uptake of HRP by the liver. 
These results confirm earlier reports that HRP is rapidly cleared 
from circulation by specific recognition (Rodman et al, 1978), and in vitro 
studies that have demonstrated specific binding to and uptake of HRP by the 
bone marrow macrophages (Lang and Chastellier, 1985) and liver sinusoidal 
cells (Straus, 1981). Here, we have shown that uptake of HRP by the liver 
is dependent upon by a mannose receptor mediated pathway. These results 
are of significance as HRP is often used a marker of non-specific uptake in 
vivo. 
Competitive studies with dextran indicated that dextran had no effect 
on the uptake of HRP or dextran- HRP by the liver, and the uptake in the 
presence or absence of dextran was the same. Though dextran on its own 
does not inhibit the uptake of HRP, however on covalent attachment to HRP 
it appears to be forming a steric barrier around the enzyme and thereby 
reducing the interaction of the mannose residues of HRP with mannose 
specific receptors on kupffer cells. Significantly, though dextran reduces 
the interaction of HRP with mannose receptor, it does not inhibit it com-
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pletely and the uptake of dextran-HRP conjugate by the mannose receptor 
mediated pathway into the liver is limited. The dextran-HRP conjugarte 
therefore retains its ligand property to some extent. The retention of ligand 
property even after modification with some hydrophilic polymer is important 
when the ligand depends upon this property for its action. Interleukin-2 for 
example, depends upon its ability to bind to the receptor for its action and 
this property has been shown to be retained even after modification with 
PEG (Katre g/a/, 1987). 
2.4.4 Effect of covalent modification with dextran on the intracellular 
stability of HRP 
40% of the free HRP administered accumulated in the liver within 
30 minutes. Thereafter, there was a rapid decrease in the amount of enzyme 
remaining in the liver. Of the total HRP present in the liver after 30 
minutes, only 35% could be detected after six hours and no enzyme could 
be detected after 24 hours. The uptake of dextran-HRP conjugate by the 
liver was slower and only 13% of the enzyme activity administered could 
be detected after 30 mins. Maximal uptake of the conjugate (17%) occured 
one hour after administration. Thereafter, there was a gradual decrease in 
the amount of enzyme activity remaining in the liver. Of the total dextran-
HRP conjugate present in 30 minutes, 91% could be detected six hours after 
administration and 9% remained even 24 hours after administration. Fig 4 
gives the comparison of tissue levels of HRP and dextran-HRP conjugate 
when the amount accumulated within 30 minutes is considered to be 100%. 
A significant proportion (" 30%) of the enzyme accumulated in the 
liver was found to be associated with the mitochondrial/lysosomal fraction. 
Fig 5 compares the degradation of HRP and dextran-HRP conjugate in this 
fraction when the amount of enzyme activity present in 30 minutes is con-
sidered to be 100%. Almost 50% HRP was degraded within 1 hour, while 
the dextran-HRP conjugate was not affected at all in the same period of 
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FIGURE 4 
COMPARISON OF THE AMOUNT OF HRP ( • ) AND DEXTRAN-
HRP (B3) REMAINING IN THE LIVER AT VARIOUS INTERVALS 
OF TIME AFTER ADMINISTRATION 
2.5 /ig HRP and dextran-HRP were injected i.v. into three swiss albino 
mice in each group. Animals were sacrificed after various intervals of 
time. Livers were resected, weighed, and homogenised. HRP was assayed 
by ELISA. Data is expressed as percentage of liver concentration 30 
minutes after administration + SD. 
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FIGURES 
COMPARISON OF THE AMOUNT OFHRP(B)AND DEXTRAN-
HRP (S) REMAINING IN THE MITOCHONDRIAL/LYSOSOMAL 
FRACTION OF THE LIVER AT VARIOUS INTERVALS OF TIME 
AFTER ADMINISTRATION 
2.5 fig HRP either free or conjugated with dextran was injected i.v. into 
three swiss albino mice in each group. Animals were sacrificed after various 
intervals of time. Livers were resected, weighed, homogenised, and subject-
ed to subcellular fractionation. HRP was assayed in the mitochondrial/lyso-
somal fraction by ELISA. Data is expressed as percentage of 
mitochondrial/lysosomal concentration 30 minutes after administration ±_ 
SD 
time. Twenty four hours later 8% of the dextran-HRP conjugate and no 
free enzyme could be detected in the lysosomes. The conjugate it seems is 
more resistant than the free enzyme to proteolytic degradation in the acidic 
milieu of the lysosomes. 
Though the dextran-HRP conjugate appears to be more stable in the 
liver, no conclusions about stability could be drawn from this experiment as 
the rate and the amount of uptake of the free enzyme was much higher than 
that of the dextran-HRP conjugate. Also, the longer survival of the dextran-
HRP conjugate in the liver may be due to gradual uptake of the conjugate 
from the circulation and not due to decreased degradation. 
2.4.5 Effect of covalent modification with dextran and liposomal encap-
sulaton on the stability of HRP in the liver. 
In the next experiment, liposomes were chosen as carriers of both 
free HRP and dextran-HRP conjugate, in order to deliver them both to the 
liver at the same rate. Multilamellar vesicles (MLVs) prepared by the brief 
sonication method could encapsulate 7-10% of both free HRP as well as 
dextran-HRP conjugate. When administered intravenously, 47-50% of the 
liposomally encapsulated HRP, both free and conjugated with dextran, 
accumulated in the liver within 30 minutes. Thereafter there was a gradual 
reduction in the amount of enzyme present in the liver, and only about 60% 
of HRP or dextran-HRP accumulated could be detected six hours later. 
Interestingly, while free HRP was further degraded till only negligible 
amounts could be detected after 24 hours, the degradation of dextran-HRP 
was slower and 40% of the enzyme accumulated could still be detected 24 
hours after administration. This conclusively proves that the dextran-HRP 
conjugate is more stable than the free enzyme. Encapsulation into li-
posomes seems to protecting the free enzyme also from proteolytic degrada-
tion as can be seen by comparing the stability of free HRP and liposomally 
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encapsulated HRP. Fig 6 compares the tissue levels of liposomal HRP and 
dextran-HRP when the amount accumulated in 30 minutes is considered to 
be 100%. 
An analogous situation was observed in the mitochondrial/lysosomal 
fraction as well. The rate of degradation of the dextran-HRP conjugate was 
much slower as compared to that of the free enzyme. In fact there seems to 
be an enrichment of the conjugate in this fraction. The reason for this 
increase in the lysosomes is not clear. This may be due to a synergistic 
effect of enhanced stability in the lysosomes as well as decreased release of 
the conjugate from the lysosomal membrane to the cytosol. 70% of the con-
jugate present in lysosomes at 30 minutes could still be detected 24 hours 
later compared to only about 5% of the unconjugated HRP (Fig 7). 
It therefore appears that covalent modification of the enzyme with, 
an inert sugar polymer, dextran is preventing its degradation in the liver. 
Though the exact mechanism responsible for this is not as yet known, it may 
be due to protection against degradation. It has been shown in in vitro stud-
ies that enzyme- dextran conjugates exhibit enhanced resistance to degrada-
tion by proteolytic enzymes (Melton et al, 1987, Yasuda et al, 1990). 
Several factors were thought to be responsible for the enhanced 
circulatory life of dextran-enzyme conjugate. They may also be responsible 
for the intracellular stability. Intramolecular crosslinking between protein 
and dextran is believed to result in several linkages in different places there-
by conferring conformational stability to the tertiary structure of the protein 
(Marshall and Rabinowitz, 1976, Marshall, 1978). Hydrogen bonding 
between the two components of the conjugate is thought to provide addition-
al resistance to unfolding and thereby inactivation (Klibanov, 1979). It may 
also be responsible for the enhanced stability of the conjugate. 
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nGURE6 
COMPARISON OF THE AMOUNT OF LIPOSOMALLY DELIV-
ERED HRP (BD AND DEXTRAN-HRF ( S ) REMAINING IN THE 
LIVER AT VARIOUS INTERVALS OF TIME AFTER ADMINIS-
TRATION 
2.5 fig liposomally encapsulated HRP and dextran-HRP were injected i.v. 
into three swiss albino mice in each group. Animals were sacrificed after 
various intervals of time. Livers were resected, weighed and homogenised. 
HRP was assayed by ELISA. Data is expressed as percentage of liver 
concentration 30 minutes after administration + SD. 
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HGURE? 
COMPARISON OF THE AMOUNT OF LIPOSOMALLY DELIV-
ERED HRP (•) and DEXTRAN-HRP ( S ) REMAINING IN THE 
MITOCHONDRIAL/LYSOSOMAL FRACTION OF THE LIVER AT 
VARIOUS INTERVALS OF TIME AFTER ADMINISTRATION 
Liposomally encapsulated HRP and dextran-HRP were injected i.v. into 
three swiss albino mice in each group. Animals were sacrificed at various 
intervals of time after administration. Livers were resected, weighed, 
homogenised, and subjected to subcellular fractionation. HRP was assayed 
in the mitochondrial/lysosomal fraction by ELISA. Data is expressed as 
percentage of mitochondrial/lysosomal concentration 30 minutes after 
administration. 
Naturally occurring lysosomal hydrolases are glycoproteins and they 
are remarkably stable in the acidic milieu of the lysosomes. Although HRP 
is also a glycoprotein but it is rapidly degraded by the lysosomal enzymes. 
However, we have been successful in enhancing the intracellular stability of 
HRP by extensively glycosylating it with dextran. This is the first time that 
retention of catalytic activity of a dextran-enzyme conjugate over extended 
periods of time has been reported intracellularly and intralysosomally. Earli-
er reports on the intracellular stability of dextran-enzyme conjugates had 
restricted themselves to radiolabeling studies and they had not explored the 
intracellular catalytic stability of the enzymes (Blomhoff^r al, 1983., Melton 
et aly 1987). Melton et al had used dextran as a carrier of the enzyme for 
delivery into the liver, and only about 10% of the enzyme administered 
could be delivered to the liver by this method. 
Liposomes are not only capable of delivering a much larger percent-
age of the administered enzyme to the liver, they also protect the entrapped 
enzymes in circulation and are therefore much better carriers of enzymes. 
Dextran-HRP conjugate can be considered to be a model system for 
enhancing the in vivo stability of enzymes. The enhanced stability of 
enzymes and the use of liposomes for targetting would be of great signifi-
cance in the treatment of a number of inherited metabolic disorders where 
the lesion is in the absence of an enzyme. Enzyme therapy of such disorders 
is not very successful due to the instability and foreign nature of enzyme 
administered. Repeated administration of the enzyme which is a foreign 
protein leads to adverse immunological reaction. Finally the enzyme upon 
reaching the target cells is degraded rapidly by the lysosomal hydrolases. 
Use of liposomes not only protects the encapsulated enzyme but it is also 
possible to targets it to the diseased tissue. Once at the diseased site the 
modified enzyme can now function for a longer period of time and thereby 
show enhanced efficacy. This suggest a new approach to enzyme therapy for 
the treatment of storage disorders. 
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CHAPTER III 
3.1 INTRODUCTION 
To assess the therapeutic potential of enzymes, after their modification with 
hydrophilic polymers, in the treatment of storage disorders, a model storage 
condition was produced in the livers of mice. Dextran an inert polymer of 
D-glucose units linked predominently a-D (l-->6) was chosen as a model 
compound to simulate a lysosomal storage disorder. It is biocompatible and 
is not degraded in mice in the absence of the enzyme dextranase. Intraperi-
toneal administration of dextran has been shown to increase the density of 
liver lysosomes (Baudhuin et al, 1965). Colley and Ryman (1976) in their 
studies produced a model storage disorder in rats by intraperitoneal adminis-
tration of dextran. The amount of dextran thus accumulated in the liver 
was however very small (10% of the amount administered) and it took 
almost 24 hours for it to accumulate. To accumulate larger quantities of 
dextran in the liver in shorter periods of time, we decided to use liposomes 
as carriers for the delivery of dextran to the liver lysosomes. Liposomes are 
rapidly removed from the circulation by the kupffer cells of the liver, and 
therefore serve as efficient carriers of dextran. Dextran used for producing 
the model storage condition was fluorescently tagged with FITC to fecilitate 
its in vivo detection. 
As dextran was the substrate accumulated in the liver, the enzyme 
used for enzyme therapy was dextranase. Dextranase catalyses the endohy-
drolysis of 1,6 a-glucosidic linkages in dextran. It is produced by a variety 
of micro-organisms specially by molds and bacteria (Janson and Porath, 
1966). Industrial sources of dextranase are species of Penicillium (Novo, 
1977) and Chactomium (Miles, 1983). This enzyme has been successfully 
used to treat sugars contaminated with dextran (Koenig and Day, 1988). 
In their studies on enzyme therapy for the treatment of storage 
disorders, Colley and Ryman (1976) produced a model storage disorder in 
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rats and compared the therapeutic efficacy of free and liposomally encapsu-
lated dextranase in the degradation of the stored dextran. They observed 
that both free and liposomally delivered dextranase were capable of degrad-
ing the stored material. This enzyme is therefore taken up by the liver even 
when it is not encapsulated into liposomes. To monitor the presence of 
dextranase in the liver, CoUey and Ryman (1976) developed an in vitro 
assay using radiolabelled dextran. Enzyme activity in the tissue was moni-
tored by treating radiolabelled dextran with a tissue aliquot containing dex-
tranase. The degraded dextran was measured by assaying the radioactivity in 
the supernatant after alcohol precipitation of intact dextran. They showed 
that though the amount of free dextranase in the tissue is considerably less 
than when it is delivered after encapsulation into liposomes, it is still 
enough for the degradation of the stored dextran. 
This study was one of the first few, which demonstrated the possibil-
ity of enzyme therapy in an in vivo model and showed that liposomes can be 
used as carriers of the enzyme for delivery to the liver lysosomes, which are 
the sites of substrate accumuladon in such disorders. It however did not 
give any information about the stability of the administered enzyme inside 
the cell, its capacity of preventing further accumulation of the substrate or 
the frequency of the therapy required. 
As discussed earlier, a number of studies have demonstrated that it is 
possible to enhance the circulatory life of enzymes by their modification 
with PEG or with dextran. Such long circulating therapeutic enzymes have 
been shown to have enhanced efficacy in the treatment of a number of 
disorders (Hershfield et al, 1987; Chua et al, 1988). 
As it was not possible to use dextran for covalently modifying dex-
tranase, we decided to use another hydrophilic polymer "PEG" for the 
purpose. PEG is a linear, unchanged, non-immunogenic compound with a 
general structure HO-CCHj-CHj)^-©!!. It is compatible with blood and is 
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available in various molecular weight ranges. The hydroxyl groups are 
available for modification. They however cause cross linking of the 
conjugates. To overcome this complication, a monofunctional derivative of 
PEG (methoxy PEG), with one hydroxyl group available for modification, 
is used. 
, Enzymes modified with PEG exhibit enhanced half lives in circula-
tion. This remarkable ability of PEG in enhancing the circulatory life of 
enzymes may be attributed to an increase in the hydrophilicity of the en -
zyme surface as each molecule of PEG can bind three molecules of water. 
The uptake of molecules from the circulation is thought to be mediated by 
some as yet unidentified serum components called "opsonins". These 
opsonins bind to the hydrophobic regions of the molecule. Making the 
surface hydrophilic would therefore be expected to reduce the uptake by the 
RES (Van Oss et al, 1975; Ilium and David, 1982; Ilium and Davis, 1983). 
Such PEG-modified enzymes are more stable against degradation by 
proteolytic enzymes (Abuchowski et al, 1977). PEG causes a restructuring 
of water molecules around itself, due to its high affinity for the water mol-
ecules. This leads to a steric exclusion of macromolecules particularly 
proteins, from regions of water occupied by the inert PEG (Atha and 
Ingham, 1981). Blume and Cevc (1990) have calculated the thickness of the 
surface region inaccessible to water-soluble proteins to be " 2 nm for DSPC 
liposomes containing 10% DSPE-PEG. 
This exclusion of proteins from regions of water occupied by PEG 
may be responsible for the resistance of PEG modified enzymes to proteoly-
tic degradation. Blomhoff ei al (1983) and Melton et al (1987) have report-
ed that enzymes modified with, hydrophilic polymers such as dextran, 
exhibit enhanced stability in side the cell. Their conclusions are however 
based only on the radioactivity data, and give no indication about the cataly-
tic stability of these enzyme conjugates. It can however be postulated that 
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the exclusion of proteins from regions of water occupied by PEG may also 
protect the PEG modified enzymes from degradation both intracellularly and 
intralysosomally. Dextranase was therefore modified with PEG to try and 
protect it from degradation by the lysosomal hydrolases. 
In this section we report a model storage condition in the livers of 
mice by intravenously administering liposomally encapsulated dextran. The 
efficacy of free or liposomally encapsulated dextranase and PEG-dextranase 
in the degradation of the sotred dextran, and in preventing its further 
accumulation has been compared. 
The effect of covalent modification of dextranase with mPEG, on its 
intracellular stability has also been studied. 
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MATERIALS 
Dextranase (EC 3.2.1.11) from Penicilliwn species, specific activity: 
1000 U /4,3 mg protein. Methoxy PEG activated with cyanuric chloride (av 
mol wt. 5000), dextran (av mol wt. 40,000), FITC- dextran (av mol wt. 
20,000), cholesterol, dicetylphosphate and Sephadex G-75 were purchased 
from Sigma Chem Co., St. Louis, MO, USA. Egg phosphatidylcholine 
(EPC) was purchased from Nippon Oil and Fat Co., Hyogo, Japan. Biogel 
P-200, electrophoresis grade acrylamide, N,N'-methylene bis- acrylamide, 
Tris, N,N,N',N'-tetramethylene diamine (TEMED), sodium dodecyl sul-
fate, and low molecular weight standard for SDS-PAGE were purchased 
from Bio Rad Laboratories, Richmond, CA, USA. Centriflo ultrafiltration 
cones (CF 25; mol wt cut off 25,000) were purchased from amicon div., 
W.R. Grace and Co., USA. Carrier free Na ^^I was purchased from 
Bhabha Atomic Research Centre, Bombay, India. 
Animals : Male Balb/c mice (20-25 g) were purchased from LAIS Centre, 
National Institute of Nutrition, Hyderabad. 
3.3 METHODS 
3.3.1 Preparation of PEG-dextranase coi\jugate 
PEG-dextranase conjugate was prepared following the method de-
scribed by Hadley and Sato (1989) with some modifications. In brief, 4 mg 
dextranase was dissolved in 2 ml of 0.1 M phosphate buffer pH, 8.0. 150 
mg PEG (activated with cyanuric chloride) was added and the reaction was 
allowed to proceed for two hours with constant stirring at 4^C. Excess PEG 
was removed by repeated ultrafiltration in CF25 filters at 1000 x g for 30 
minutes. It was observed that dextranase lost all its enzyme activity upon 
conjugation with PEG. This lead us to modify the conjugation proce-
dure, and the conjugation reaction of dextranase was carried out in the 
presence of dextran, 200 mg dextran was added to 2ml phosphate buffer 
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(0,1M, pH 8.0) containing 4mg dextranase. This was followed by the addi-
tion of 150 mg of PEG (activated with cyanuric chloride). Reaction was 
allowed to proceed as before. Excess PEG was removed by repeated ultra-
filtration in CF25 filters at 1000 x g for 30 minutes. 
25-30% of the enzyme activity was recovered by this method. 
3.3.2 Enzyme Assay for Dextranase 
Dextranase was assayed by a modification of the method described 
by Janson and Porath (1966). Briefly, 0.1 ml enzyme dilution was added to 
1.9 ml of 2% dextran in 0.1 M phosphate buffer pH, 6.0 at 37^C. The 
reaction was stopped at timed intervals by removing one ml of the reaction 
mixture, transferring it to tubes containing 1 ml dinitrosalicylic acid (DNS) 
reagent, and incubating in a boiling water bath for 15 minutes. The tubes 
were cooled to room temperature and 10 ml water added to them. Absor-
bance was monitored at 540 nm. 
DNS reagent was prepared by dissolving 1.0 gm of 3, 5-dinitrosali-
cylic acid in 50 ml distilled water. 30 gms of sodium potassium tartarate 
was slowly added to it with constant stirring. It was followed by the addi-
tion of 20 ml of 2N NaOH. The reagent was diluted to a final volume of 
1(X) ml with disfilled water. 
Although this method of enzyme estimation served well for the in 
vitro analysis of dextranase, however, it could not be used for monitoring 
the presence of the enzyme in vivo. This method of enzyme estimation is 
based on the assay of the reducing sugars released upon degradation of 
dextran by dextranase. Liver itself contains a lot of reducing sugars and the 
blanks were therefore very high. Small, or even large amounts of dextranase 
administered could not be detected in vivo due to the high blanks. It was 
therefore necessary to develop some other method for the estimation of 
intracellular levels of dextranase. 
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3.3.3 In vivo enzyme assay for dextranase 
The in vivo assay developed by Colley and Ryman (1976) was not 
used as it involved extensive use of radiolabeled dextran. We therefore took 
a 2% solution of FITC-dextran in O.IM phosphate buffer, pH 6.0 as the 
substrate. It was treated with different concentrations of enzyme at 37^C for 
one hour. Reaction was stopped by transferring 0.1ml aliquots to 1 ml PBS 
(0.25 M, pH 7.4) kept in ice. 0.1 ml of this was immediately loaded on to a 
Sephadex G-75 (30 x 1cm) column equilibrated with PBS. 2 ml fractions 
were collected at a flow rate 20ml/hour, and assayed for fluorescence at 
495/520. Fig. 1 gives the gel filtration profile of FITC-dextran after treat-
ment with different concentrations of dextranase. 
No change in the elution profile of FITC-dextran was observed upto 
a concentration of 50ng dextranase. Thereafter, it was observed that with 
increasing concentrations of the enzyme, there was a gradual shift in the 
peak towards a lower molecular weight fraction, with a concomitant de-
crease in peak height with respect to the control. 100 ng dextranase caused a 
62 % decrease in peak height. One unit of enzyme activity was arbitarily 
defined as "1 % decrease in the peak height when the fluorescence in the 
peak fraction of the untreated control is taken to be 100 %." By this defini-
tion 100 ng dextranase corresponds to 62 enzyme units. All further calcula-
tions for estimation of enzyme in tissues were done with respect to this 
value. 
3.3.4 lodination of Dextranase 
Dextranase was iodinated according to the method described by 
Hunter et at (1978). 250 /iCi Na^^I was added to 2 mg dextranase in 200 
/il PBS (.025M phosphate buffer pH, 7.4 containing 0.15 M NaCl) followed 
by the addition of 10 )Ltl of chloramine-T solution (20 mg/ml in PBS). The 
reaction mixture was shaken for 3 minutes behind a lead shield. 10 pi\ 
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FIGURE 1 
GEL FILTRATION PROFILE OF FITC-DEXTRAN ON A SEPHA-
DEX G-75 COLUMN, AFTER TREATMENT WITH DIFFERENT 
CONCENTRATIONS OF DEXTRANASE. 
a) FITC-dextran was treated with 50 ng (A), 100 ng (T), 200 ng (V), 300 
ng (D ) and 500 ng ( • ) of dextranase, and appropriately diluted aliquots 
loaded on a sephadex G-75 column. 1 ml fraction collected were monitored 
for fluorescence at 495/520. (•) untreated control 
sodium metabisulifite (20 mg/ml in PBS) and 10 /il KI (30 mg/ml in PBS) 
were added to stop the reaction. 
The unreacted Iodine was removed by gel filtration on a sephadex G-
25 column (20 x 1cm) equilibrated with PBS containing 50 /xg/ml BSA. 
The sample was eluted with the same buffer at a flow rate of 15 ml/hour, 
and 1 ml fractions were collected. 10 /il aliquots taken from the fractions 
collected were diluted to 1 ml and counted in a LKB autogamma counter. 
^^I-dextranase had a specific activity of 8.6 x 10^ cpm//ig protein. 
3.3.5 Conjugation of radiolabeled dextranase with PEG 
After labeling, a portion of the iodinated dextranase was coupled 
with the activated PEG. The method used for conjugation was the same as 
described before. In this case also the conjugation reaction of dextranase 
was carried out in the presence of dextran. 
3.3.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis was carried out in vertical 
slab gels according to the method of Laemmli et al (1973). 10 /xl of dextra-
nase or purified PEG-dextranase containing 5 /ig protein was added to an 
equal volume of sample buffer giving a final concentration of 2% (w/v) 
SDS, 125mM Tris-HCl (pH 6.8) and 10% (v/v) glycerol with a trace of 
bromophenol blue as the tracking dye. The sample was loaded on a 10% 
seperating gel with a 3% stacking gel. The running buffer for electrophore-
sis was composed of 0.05M Tris, 0.0112M glycine and 0.1% SDS, pH 8.5. 
The mobility of PEG-dextranase conjugate was compared with that of simi-
larly treated free dextranase. 
3.3.7 Encapsulation of dextranase and PEG-dextranase into Liposomes 
Liposomes were prepared using EPC, Choi, and DCP in the molar 
ratio of 7:2:2 according to the method described by Surolia et al (1975). 
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The lipids (20 mg) were dissolved in a 2:1 mixture of chloroform - metha-
nol and a thin dry film was made on the sides of a round bottom flask by 
rotary evaporation of the solvents at 37°C under reduced pressure. The 
flask was kept overnight in a vacuum desicator at 4*'C. The film was subse-
quently hydrated with 1 ml PBS containing 100 /xg dextranase or PEG-
dextranase conjugate. The dispersion was completed by a brief sonication 
(30 seconds) in a MSE ultrasonicator and then kept at room temperature for 
30 minutes. The unentrapped enzyme was removed by repeated washing the 
liposomes with PBS in an ultracentrifuge at 1,05,(XX) X g for 30 minutes, 
till no enzyme activity could be detected in the supernatant. Percentage 
entrappment in liposomes was studied by assaying the enzyme activity in the 
presence of 0.1 % Triton X-100. 
*^I-dextranase and PEG-^^^I dextranase were also entrapped into 
liposomes following the same procedure. The unentrapped enzyme was 
removed by repeated washing with PBS in an ultracentrifuge at 105,000 xg, 
till there was no radioactivity in the supernatant. The liposomal pellet was 
resuspended in PBS and an aliquot was taken for radioactive counting. 
3.3.8 Encapsulation of FITC-dextran into liposomes 
Two lipid compositions were used for encapsulating FITC-dextran 
into liposomes. Positively charged liposomes were prepared using EPC, 
chol and stearylamine in the molar ratio of 7:2:2 and negatively charged 
liposomes were made using EPC, Choi and DCP in molar ratio 7:2:2. A 
thin dry film of lipids was made on the sides of a round bottom flask as 
described earlier. The film was hydrated for one hour with 1 ml PBS con-
taining 15 mg FITC-dextran/20 mg total lipid. The dispersion was sonicat-
ed for 30 seconds in an MSE ultrasonicator, and kept at room temperature 
for 30 minutes. Unentrapped FITC-dextran was removed by repeated 
washing with PBS in an ultracentrifuge at 1,00,CXX) x g. Liposomes were 
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washed till there was no fluorescence in the supernatant. Percentage entrap-
ment was calculated by resuspending the liposomal pellet in PBS and assay-
ing an aliquot for fluorescence. 
3.3.9 Fluorometric determination of FITC-dextran 
Appropriate dilutions of sample containing FITC- dextran were 
analysed in a Shimadzu RF-540 spectro fluorophotometer at excitation 
495nm and emission 520nm. 
AMMAL EXPERIMENTS 
3.3.10 Accumulation of FITC-dextran in the liver 
In order to produce a model storage condition in the liver of mice, 
1.5 mg of FITC-dextran either free, encapsulated into positively charged 
(EPC, Choi, stearylamine) liposomes, or into negatively charged 
(EPC,Chol,DCP) liposomes, was administered intravenously via the tail 
vein into three mice in each set. Animals were sacrificed 30 minutes after 
injection. Livers were removed, washed, weighed, homogenised and sub-
jected to subcellular fractionation. 
To assess the amount of FITC-dextran accumulated in the liver, at 
various intervals of time after administration, nine animals were injected 
with 1.5 mg of liposomally encapsulated (PC:Chol:DCP, 7:2:2) FITC-
dextran. Three mice each were sacrificed after 30 minutes, 6 hours and 24 
hours. Livers were removed, washed in saline, homogenised and subjected 
to subcellular fractionation. The homogenate and the mitochondrial/lyso-
somal fraction were frozen, thawed and assayed for fluorescence. A portion 
of the homogenate was subjected to gel filtration on a Bio gel P200 column 
to check for the intactness of the accumulated FITC- dextran in the liver. 
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In another experiment, three mice were given 1.5 mg of liposomal 
(EPC:Chol:DCP, 7:2:2) FITC-dextran thrice at intervals of 30 minutes. 
Animals were sacrificed six hours after the first injection. Livers were 
removed, washed in saline, and homogenised. The homogenate was frozen, 
thawed and assayed for fluorescence. 
3.3.11 Subcellular fractionation 
An aliquot of the homogenate was kept aside and the rest was frac-
tionated by differential centriftigation into nuclear, mitochondrial/lysosomal 
and soluble fractions (Gregoriadis and Sourkes, 1967). Briefly, liver was 
homogenised in PBS and the volume was made upto 10 ml. One ml aliquots 
of the homogenate were kept aside for estimation of the total fluorescence in 
the liver. The rest was centrifuged at 1000 x g for 15 minutes. The pellet 
containing nuclei, unbroken cells and cell debris was discarded. The super-
natant was centriftiged at 12000 x g for 30 minutes. Volume of the pellet 
containing the mitochondrial/lysosomal fraction was made upto 3 ml by 
resuspending it in PBS. The homogenate and the mitochondrial/lysosomal 
fraction were then assayed for fluorescence. 
3.3.12 Degradation of the stored FITC-dextran with free or liposomally 
entrapped dextranase 
0.2 ml liposomes (EPC:Chol:DCP, 7:2:2) containing 1.5 mg of 
FITC-dextran were administered intravenously via the tail vein of mice, 
followed 30 minutes later by the administration of either empty liposomes, 
by one unit (4.3 /xg) free dextranase or by one unit (4.3 fig) of liposomally 
encapsulated dextranase. Three animals from each set were sacrificed six 
hours after the first injection. Livers were resected, washed in saline 
weighed and subjected to subcellular fractionation as described before. 
After freezing, thawing and centriftigation at 1(XX) rpm for 5 minutes, ali-
quots of the supernatant were assayed for fluorescence. 0.5 ml supernatant 
of the homogenate was subjected to gel filtrafion on the Biogel P-200. 
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3.3.13 Gel filtration of the accumulated FlTC-dextran after treatment 
with free or liposomally encapsulated dextranase 
To check for the degradation of the stored FITC- dextran after 
treatment with saline liposomes, free or liposomally encapsulated dextra-
nase, the homogenate was frozen, thawed and centrifuged at high speed in a 
mini centrifuge. 0.5 ml supernatants were loaded on a Biogel P-2(X) column 
(25 X 2.5 cms) equilibrated with PBS. 2 ml fractions were collected in the 
same buffer at a flow rate of 15 ml/hour. The fractions were assayed for 
fluorescence as described before. 
3.3.14 In vivo life of ^^I-dextranase and *^I dextranase-PEG conjugate 
To monitor the presence of dextranase in the liver after various 
intervals of time, it was labeled with ^^siQdine. Each mouse was intra-
venously injected with 0.2 ml dextranase (5-6 x 10^ cpm), either free or 
conjugated with PEG. In another set of experiments, 5-6x 10* cpm of lipo-
somally encapsulated ^^ I^ dextranase or PEG-^^^I dextranase were intra-
venously administered via the tail vein of mice. In both cases, three animals 
were sacrificed from each set one hour, 3 hours, 6 hours, 12 hours and 24 
hours after administration. 0.1 ml of 20 mM EDTA in PBS was taken in a 
syringe and 1ml blood was drawn from the heart. 0.3 ml aliquots of blood 
were taken for radioactive counting. Livers were resected, washed and 
homogenised in PBS. 2 ml aliquots were taken for radioactive counting and 
the rest was fractionated into nuclear, mitochondrial/lysosomal and soluble 
fractions as described before. The entire mitochondrial/lysosomal pellet 
was assayed for radioactivity. 
3.3.15 Comparison of the intracelluar and intralysosomal retention of 
catalytic activity of various formulations of dextranase 
A study was undertaken to see whether the enzyme was catalytically 
active inside the cells. 1 jug each of dextranase, PEG-dextranase, liposomal 
dextranase or liposomal PEG-dextranase were administered into sets of three 
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mice each. This was followed six hours later by the administration of lipo-
somal FITC-dextran. Animals were sacrificed an hour after the second 
injection. 
In another set of experiments animals were intravenously adminis-
tered with 1 ug of either dextranase, PEG-dextranase, liposomal dextranase 
or liposomal PEG-dextranase followed twenty four hours later by liposomal 
FITC-dextran. Animals were sacrificed one hour after the second injection. 
Livers were removed, washed in saline, blotted, weighed and 
homogenised in PBS. An aliquot of the homogenate was kept aside and the 
rest was fractionated into nuclear, mitochondrial/lysosomal and soluble 
fractions as by described earlier (Gregoriadis and Sourkes, 1967). 
The homogenate was frozen, thawed and centrifuged in a mini 
hermal centrifuge at high speed for 10 minutes. 0.1 ml aliquots of the 
supernatant were subjected to gel filtration on a Sephadex G-75 column (30 
X 1 cm) equilibrated with PBS. Samples were eluted with PBS at a flow 
rate of 20 ml/hr. A control was also run in which 100 /il of FITC-dextran 
solution (100 /ig/ml in PBS) was chromatographed on the same column. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Model storage disorder 
It is known that dextran is not degraded in mice in the absence of the 
enzyme dextranase (Bauduin et al, 1965). FITC-dextran was therefore used 
for producing a model lysosomal storage condition in mice. The presence of 
a flourescent label on dextran helped in detecting the stored material in the 
liver. An animal model for lysosomal storage disorders using dextran, had 
earlier been reported by Colley and Ryman (1976). They showed that intra-
peritoneal administration of dextran into rats caused 11 % of the adminis-
tered dextran to accumulate in the liver after 48 hours. This uptake was, 
however very small and the time taken for delivery very long. We therefore 
decided to use other methods for the accumulation of larger amounts of 
dextran within shorter periods of time. 
Upon intravenous administration only 8% of the free FITC-dextran 
injected was taken up by the liver and the amount accumulating in the ly-
sosomes was only 4% of that injected. Due to the low uptake of FITC-
dextran by the liver we decided to use liposomes as carriers for delivery into 
the liver lysosomes. Charged lipids, both cationic (stearylamine) and an-
ionic (dicetylphosphate) were included in the liposomal lipid composition. It 
is known that inclusion of charge increases the bilayer distance in MLVs 
and therefore the encapsulation efficiency (Bangham et al, 1967). Such 
multilamellar liposomes could entrap 7-10% of the FITC-dextran used for 
hydrating the lipid film. Upto 45% of negatively charged liposomes were 
taken up by the liver compared to only 30% of the positively charged li-
posomes. The negatively charged liposomes were also more efficient in 
delivering the entrapped FITC-dextran to the liver lysosomes almost 14% of 
the negatively charged liposomes accumulated in the liver lysosomes within 
30 minutes compared to only 2% of the positively charged liposomes (Table 
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TABLE I 
UPTAKE OF VARIOUS FORMULATION OF FITC-DEXTRAN 
BY THE LIVER 
Formulation of 
FITC-dextran 
administered 
Liver uptake 
% of injected 
dose 
Mitochondrial/Lysosomal 
fraction 
% of injected 
dose 
% of total 
liver uptake 
Free 
PC:ChoI:SA 
(7:2:2) 
PC:Chol:DCP 
(7:2:2) 
8.5 ± 0.6 
29.8 ± 3 
45.6 ± 4 
3.8 ± 0.5 
2.3 ± 0.7 
13.8 ± 3 
45.2 ± 3 
7.8 ± 2 
32.0 -f 3 
1.5 mg FITC-dextran either free, encapsulated into positively charged 
(PC:Chol:SA) liposomes, or into negatively charged (PC:Chol:DCP) li-
posomes was administered intravenously into three Balb/c mice in each set. 
Animals were sacrificed after 30 minutes. Livers were resected, washed, 
weighed, homogenised and subjected to subcellular fractionation. Aliquots 
of the homogenate and mitochondrial/lysosomal fractions were frozen, 
thawed and assayed for fluorescence at 495/520. Values are represented as 
mean of three experiments ± S.D. 
I). These results were in agreement with earlier reports that negatively 
charged liposomes are taken up by the liver more rapidly than the positively 
charged or neutral liposomes (Gregoriadis and Neerunjun, 1974). 
We therefore decided to use negatively charged liposomes for 
accumulating FITC-dextran in the liver lysosomes. 
In order to check degradation, if any, of the FITC-dextran accumu-
lated in the liver, animals were sacrificed 30 minutes, 6 hours, and 24 hours 
after injection and the total fluorescence in the liver monitored. Gel filtra-
tion profile of FITC-dextran was monitored in the liver 30 minutes and 24 
hours after administration. In both cases FITC-dextran elutes at the same 
position as the control FITC-dextran solution indicating no degradation of 
the stored material. There is however a reduction in the total amount of 
FITC- dextran accumulated from 45% in 30 minutes to 25% after 24 hrs 
(Table II). This may be due to a gradual removal of dextran from the cell. 
Multiple injections of liposomal FITC-dextran at 30 minute intervals 
resulted in a larger accumulation (680 /xg) of FITC-dextran in the liver 
compared to single injections (320 /ig) (Table III). The percentage uptake 
of the total FITC-dextran administered was however reduced. Although 
more substrate could thus be accumulated, multiple injections caused the tail 
to acquire a blotched appearance making further injections difficult. All fur-
ther experiments to test the efficacy of enzyme therapy in the degradation 
of the stored FITC-dextran were therefore carried out after a single injection 
of liposomal FITC-dextran. 
3.4.2 Degradation of the stored FITC-dextran by free and iiposomally 
encapsulated dextranase 
In the absence of any enzyme capable of degrading the stored FITC-
dextran, there was only a slow decrease in the amount of FITC-dextran 
present in the liver. Administration of one unit (4.3 /xg) of liposomal dex-
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TABLE II 
AMOUNT OF FITC-DEXTRAN REMAINING IN THE LIVER AT 
VARIOUS INTERVALS OF TIME AFTER ADMINISTRATION 
Time After 
Administra-
tion 
30 min 
6 hrs 
24hrs 
Liver uptake 
% of injected 
dose 
45.6 ± 4 
34.0 ± 4 
25.0 ± 0.5 
Mitochondrial/Lysosomal 
fraction 
% of injected 
dose 
13.8 ± 3 
9.4 ± 0.5 
6.9 ± 0 . 1 
% of total 
liver uptake 
2.0 ± 0.3 
28.7 ± 4 
30.9 ± 1 
1.5 mg of liposomally encapsulated (PC:Chol:DCP, 7:2:2) FITC-dextran 
was administered intravenously via the tail vein into nine Balb/c mice. Sets 
of three mice each were sacrificed after 30 minutes, 6 hours and 24 hours. 
Livers were resected, washed, weighed, homogenised and subjected to 
subcellular fractionation. Aliquots of homogenate and mitochondrial/lyso-
somal fractions were taken and assayed for fluorescence at 495/520. Values 
are expressed as mean of three experiments ± S.D. 
TABLE III 
TOTAL AMOUNT OF FITC-DEXTRAN ACCUMULATED IN THE 
LIVER AFTER SINGLE AND MULTIPLE INJECTIONS 
No. of 
injections 
given (Total 
amount of 
FITC-dextran 
administered 
Liver uptake 
% of injected 
dose 
(amount accumu-
lated) 
Mitochondrial/Lysosomal 
fraction 
% of injected 
dose 
(amount accumulated) 
Single injection 
(1.5 mg) 
33.4 ± 3.6 
(320 ± 34 /xg) 
9.4 ± 0.5 
(89 ± 4.7 fig) 
Triple injection 
(4.5 mg) 
23.7 ± 1.2 
(680 ± 33 /ig) 
7.5 ± 0.6 
(210 ± 18 ^g) 
1.5 mg liposomally encapsulated FITC-dextran was administered intra-
venously into three Balb/c mice via the tail vein. Animals were sacrificed 
six hours later. In another experiment, three Balb/c mice were injected with 
1.5 mg liposomally encapsulated FITC-dextran thrice at 30 minute intervals. 
Animals were sacrificed six hours after the first injection. In both cases, 
livers were resected, washed, weighed, homogenised and subjected to sub-
cellular fractionation. Homogenate and the mitochondrial/lysosomal frac-
tion were assayed for fluorescence at 495/520. Values are expressed as 
mean of three experiments ± S.D. 
tranase resulted in a 50% reduction in the total FITC-dextran accumulated in 
the liver (Table IV). Gel filtration profile of FITC-dextran on a Biogel P-
200 column also shows a reduction in the peak area accompanied by a peak 
shift to a lower molecular weight fraction (Fig 2). These results indicate that 
liposomal dextranase degrades the stored FITC-dextran and the degradation 
products diffiise out of the cell. 
Interestingly free dextranase was also able to degrade the FITC-
dextran stored in the liver. Although the amount of FITC-dextran remaining 
in the liver was only 25% less than that in controls where empty liposomes 
were injected, there was peak shift to a lower molecular weight fraction 
upon gel filtration. 
These results indicate that dextran was degraded even when free 
dextranase was administered. However, the degradation was slower when 
free enzyme was given probably due to lower uptake by the liver than that 
of liposomal dextranase. This explains the higher amount of FITC-dextran 
present in the liver when free dextranase was given. 
Similar observations were earlier reported by CoUey and Ryman 
(1976) while testing the efficacy of free and liposomal dextranase in the 
treatment of a model storage condition. 
Control experiments where empty or saline liposomes were injected did not 
show any degradation of the stored dextran. 
It therefore appears that liposomes act as efficient delivery systems 
for enzymes, and the delivered enzyme is capable of degrading the intracell-
ular and intralysosomal stores of dextran. There however remains the 
problem of the intracellular and intralysosomal stability of the enzyme and 
the capacity of the administered enzyme in preventing further accumulation 
of its substrate. With this in mind we decided to conjugate dextranase with 
PEG and analyse the stability of the conjugate intracellularly. 
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TABLE IV 
EFFECT OF FREE AND LIPOSOMALLY ENCAPSULATED 
DEXTRANASES ON THE DEGRADATION OF THE 
ACCUMULATED FITC-DEXTRAN 
Enzyme 
formulation 
administered 
Saline 
liposomes 
Free 
Dextranase 
Liposomal 
Dextranase 
Total Liver 
uptake 
% of injected 
dose 
25.4 ± 0.5 
19.9 ± 2 
11.9 ± 2 
Mitochondrial/Lysosomal 
fraction 
% of injected 
dose 
6.5 ± 0.3 
4.9 ± 0.7 
4.4 ± 0.1 
% of total 
liver uptake 
26 ± 2 
25 ± 4 
31 ± 3 
1.5 mg of liposomally encapsulated FITC-dextran was administered into 9 
Balb/c mice followed half an hour later by either saline liposomes, free 
dextranase or liposomally encapsulated dextranase into sets of three mice 
each. Animals were sacrificed 6 hours after the first injection. Values are 
given as mean of three experiments ± S.D. 
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FIGURE 2 
GEL FILTRATION PROFILE OF FITC-DEXTRAN ACCUMULATED 
IN THE LIVER AFTER TREATMENT WITH DIFFERENT FORMU-
LATIONS OF DEXTRANASE. 
0.2 ml liposomes containing 1.5 mg FITC-dextran were administered via 
the tail vein into Balb/c mice followed half an hour later by either saline 
liposomes ( • ) , 1 unit (4.3 /ig) free dextranase (v ) or 1 umt(4.3ug) lipo-
somally encapsulated dextranase ( • ). Three animals from each set were 
sacrificed six hours after the first injection. Livers were resected, washed, 
weighed and homogenised. After freezing, thawing, and centriftigation at 
high speed in a mini hermal centrifuge for 5 minutes, 0.5 ml aliquots of the 
homogenate were loaded on a Bio gel P200 column. Fractions were moni-
tored for flourescence at 495/520. 
3.4.3 Characterisation of PEG-dextranase coi\)ugate 
Fig 3 compares the mobility of dextranase and PEG-dextranase on 
a 10% SDS polyacrylamide gel. While the native enzyme migrated as a 
single band of expected molecular weight, the conjugate showed a broad 
diffused band at the top of the gel indicating it higher molecular weight. No 
band corresponding to the unconjugated dextranase was seen in this lane 
indicating that all the enzyme was covalently modified with PEG. 
No conclusions about the molecular weight of the PEG-dextranase 
conjugate could be made as PEG conjugates are known to move more 
slowly on polyacrylamide gel electrophoresis than would be predicted from 
the size increase (Abuchowski et al 1977). The apparent increase in molec-
ular weight may be due to the large volume of water bound to the PEG 
conjugates. Each molecule of PEG can bind 3 molecules of water. Bode 
(1976) while earring out electrophores on cellulose acetate reported that 
polyethylene glycol of 40,000 daltons when added to the electrophoretic 
solution influences the mobility of SDS-complexed peptides as a function of 
their molecular weights. The longer the peptide, the less its mobility. The 
author attributes the decreased mobilities to entangled arms of PEG which 
form a fluid network. Entanglement with polyacrylamide may also explain 
the reduced mobility of PEG-dextranase. 
3.4.4 In vivo persistance of dextranase and PEG- dextranase 
3.4.4a Circulatory life 
When *^I dextranase or PEG-^^I dextranase were administered 
intravenously into mice, it was observed that the unmodified dextranase was 
rapidly cleared from the circulation, and only about 15% of it could be 
detected one hour later. After that only negligible amounts could be detect-
ed 6 hours and 24 hours after administration. PEG-dextranase on the other 
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FIGURE 3 
COMPARISON OF THE ELECTROPHORETIC MOBILITY OF 
DEXTRANASE AND PEG-DEXTRANASE ON A 10% SDS-PAGE. 
5 /ig of dextranase (Lane 2) and PEG-dextranase (Lane 3) were loaded on a 
10% separating gel and their mobilities compared Lane 1 gives the standard 
molecular weight markers. 
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hand showed a much longer survival in circulation. Almost 60% of the 
labeled PEG-dextranase administered was present in the circulation, one 
hour after administration and 30% of it could still be detected 24 hours 
later. Our results once again confirm earlier reports that PEG-enzyme 
conjugates exhibit an enhanced circulatory life compared to the unmodified 
enzyme (Abuchowski et aly 1977). 
Various reasons have been given for the prolonged circulatory life of 
PEG modified enzymes. The most plausible one is the reduced interaction of 
these conjugates with certain serum proteins "opsonins" which mediate the 
uptake of macromolecules by the RES. Opsonins bind to hydrophobic sur-
faces and PEG makes the surface of enzymes highly hydrophilic. Senior et 
al (1991) using a two phase partitioning system have shown that liposomes 
coated with PEG take upto 6 hours for interacting with plasma proteins 
while the interaction of uncoated liposomes with plasma proteins takes just 
one minute. A similar mechanism may also be responsible for the reduced 
interaction between plasma proteins and PEG-coated enzymes. Steric exclu-
sion of proteins from regions of water occupied by PEG may also be re-
sponsible for the reduced interaction of plasma proteins with PEG coated 
enzymes. 
When both dextranase and PEG-dextranase are encapsulated into 
liposomes and administered, they are rapidly cleared from circulation at 
similar rates. Fig 4 compares the circulatory lives of different formulations 
of dextranase. 
3.4.4b Intracellular stability 
When equal amounts of ^^I dextranase and PEG-^^I dextranase 
were intravenously administered into Balb/c mice, small portions of the 
enzyme were taken up into the liver. 12.6% of free dextranase and 19.8% 
of free PEG-dextranase conjugate could be detected in the liver one hour 
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FIGURE 4 
CIRCULATORY LIFE OF VARIOUS FORMULATIONS OF ^^ I 
DEXTRANASE. 
Each mouse was intravenously injected with 5-6x10^ cpm of either ^^I 
dextranase (•) , PEG - ^^I dextranase ( v ) , liposomally encapsulated ^^I 
dextranase (• ),or liposomally encapsulated PEG ^^I dextranase ( o ). Three 
animals from each of these groups were sacrificed at various intervals of 
time after injection. 0.1 ml of 20mM EDTA in PBS was taken in a syringe 
and blood was drawn from the heart. Aliquots were taken for radioactive 
counting. Each point represents mean of three experiments ±, SD. 
after administration (Fig 5). Subsequently free dextranase was degraded 
more rapidly in the liver than the PEG-dextranase conjugate. 24 hours 
after administration, almost 7% PEG-dextranase administered (34% of that 
present after one hour) could still be detected compared to only 2% free 
dextranase (19% of that present in the liver after one hour). 
Only small proportions of the labeled enzyme administered could be 
detected in the mitochondrial/lysosomal fraction. However, here too the 
enzyme seemed to have become more stable after modification with PEG 
(Fig 6). Only 4% of free dextranase administered could be detected one 
hour later compared to 6.5% PEG-dextranase. 24 hour after administration 
2% PEG-dextranase could still be detected compared to negligible amounts 
of the unmodified dextranase 
Although these results indicate a longer intracellular survival of the 
modified enzyme as compared to the unmodified dextranase, no conclusions 
could be drawn about the effect of covalent modification with PEG on the 
intracellular stability of the enzymes. The longer survival of the PEG-dex-
tranase conjugate in the liver may be due to gradual uptake of the conjugate 
from the circulation rather than enhanced stability in the liver. We therefore 
decided to use liposomes as carriers of both the free and the modified 
enzyme to the liver. 
Fig 5 compares the persistance of free or liposomally encapsulated 
dextranase and PEG-dextranase in the liver. Encapsulation into liposomes 
not only delivers a larger quantity of the enzyme to the liver, it also seems 
to be enhancing the intracellular and intralysosomal stability of both the 
unmodified as well as the modified enzyme. 
As can be seen from the figure, modification with PEG and encapsu-
lation into liposomes is protecting the enzyme against degradation. The rate 
of degradation of liposomally delivered PEG-dextranase is much slower 
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FIGURES 
STABILITY OF VARIOUS FORMULATIONS OF ^ I^ DEXTRANASE 
IN THE LIVER. 
Each mouse was intravenously injected with either 5-6xl0^cpm of ^^I dex-
tranase ( • ) , PEG- ^^I dextranase (v), liposomally encapsulated *^I dextra-
nase ( • ), or liposomally encapsulated PEG- ^^I dextranase (O). Three 
animals from each of these groups were sacrificed at various intervals of 
time after injection. Livers were resected, washed, weighed and homoge-
nised. Aliquots were taken for radioactive counting. Each point represents 
mean of three experiments ±_ SD. 
compared to that of all the other formulations of dextranase tested. 19% of 
the liposomal PEG-dextranase administered could still be detected in the 
liver 24 hours after administration compared to only 2, 7, and 6% of free 
dextranase, free PEG-dextranase, and liposomal dextranase respectively. 
A similar pattern is observed in the mitochondrial/lysosomal fraction 
also, when both dextranase and PEG-dextranase were encapsulated into 
liposomes and administered. Almost 8% ^^I dextranase is found in this 
fraction one hour after administration, compared to more than 14% PEG-
^^I dextranase. Six hours later 9% PEG-dextranase could be detected 
compared to only 5% dextranase and 24 hours after administration 4% 
PEG-dextranase could still be detected in this fraction compared negligible 
amounts of free dextranase. 
Fig 6 gives the amounts of labeled dextranase and PEG-dextranase 
both free or liposomally encapsulated present in the mitochondrial/lysosomal 
fraction at various intervals of time after administration. 
Dextranase appears to be more stable after modification with PEG. 
Delivery of the enzyme after liposomal encapsulation also appears to be 
stabilising the administered enzyme intracellularly as can be seen by com-
paring the amounts present in the liver before and after encapsulation of 
both dextranase and PEG- dextranase. 
Although this experiment gave a very positive indication as to the 
enhanced stability of dextranase after its modification with PEG, it failed to 
give any information about the catalytic integrity of the administered 
enzyme. Another experiment, therefore, had to be performed to check if 
the various formulations of labeled dextranase are catalytically active over a 
period of time inside the cell. 
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STABILITY OF VARIOUS FORMULATIONS OF ^^n DEXTRANASE 
IN THE MITOCHONDRIAL/LYSOSOMAL FRACTION. 
Each mouse was intravenously injected with 5-6x10^ cpm of either ^^I 
dextranase ( • ), PEG- ^^I dextranase (v),liposomally encapsulated ^^I 
dextranase ( • ), or liposomally encapsulated PEG - ^^I dextranase (o ). 
Three animals from each of these groups were sacrificed at^arious intervals 
of time after administration. Livers were resected, washed, weighed, 
homogenised and subjected to subcellular fractionation. The entire mito-
chondrial/lysosomal fraction was taken for radioactive counting. Each point 
represents mean of three experiments ±_ SD. 
3.4.5 Intracellular retention of catalytic activity of dextranase 
Fig 7 gives the gel filtration profile of FITC-dextran when it was 
administered into Balb/c mice six hours after the administration of various 
formulations of dextranase. All the formulations show a shift in peak of 
FITC-dextran towards a lower molecular weight fraction, indicating its 
degradation by the administered enzyme. The enzyme units of various 
formulations of dextranase present in the liver six hours after administration 
were calculated as described earlier in methodology. Table V gives the 
amount of dextranase remaining in the liver six hours after administration. 
Almost 15 % of the administered dose of dextranase, PEG- dextranase, and 
liposomally encapsulated dextranase could be detected in the liver six hours 
after its administration. These values resemble those obtained by the radio-
activity experiments. Surprisingly, only 2 % of PEG-dextranase adminis-
tered could be detected in the liver by this method. This value is much less 
than that obtained by the radiolabeling experiments. The reduced efficacy of 
PEG-dextranase in the degrading FITC-dextran maybe due to its prolonged 
survival in circulation and consequently reduced uptake by the liver. 
Fig 8 gives the gel filtration profile of FITC-dextran when it was 
administered into Balb/c mice 24 hours after the administration of various 
formulations of dextranase. It was observed that there was a peak shift 
towards to a lower molecular weight fraction only when liposomally encap-
sulated PEG-dextranase was injected 24 hours before the administration of 
liposomal FITC-dextran. When other formulations of dextranase namely 
free dextranase, free PEG-dextranase or liposomal dextranase were adminis-
tered 24 hours prior to the administration of liposomal FITC-dextran, there 
was only a very slight shift in the peak. Table VI gives the amounts of 
various formulations of dextranase remaining in the liver 24 hours after 
administration. 10 % of the liposomally encapsulated PEG-dextranase 
administered (or 67 % of the amount present in the liver after six hours) 
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FIGURE? 
GEL FILTRATION PROFILE OF FITC-DEXTRAN WHEN ADMIN-
ISTERED SIX HOURS AFTER THE ADMINISTRATION OF 
VARIOUS FORMULATIONS OF DEXTRANASE. 
1 /ig of either dextranase ( v ), PEG-dextranase ( a ), liposomal dextranase 
( • ) or liposomal PEG-dextranase ( • ) were administered intravenously 
into three Balb/c mice for each of these groups. This was followed six hours 
later by the administration of 1.5 mg of liposomally encapsulated FITC-
dextran. Animals were sacrificed after one hour. Livers were removed, 
washed, weighed, homogenised, and subjected to gel filtration on a sepha-
dex G-75 column.untreated control ( • ) 
TABLE V 
AMOUNT OF ENZYME REMAINING IN THE LIVER SIX HOURS 
AFTER ADMINISTERED 
Enzyme formulation 
Dextranase 
PEG-dextranase 
Liposomal 
Dextranase 
Liposomal 
PEG-dextranase 
Enzyme units 
91 (92-90) 
12(11-13) 
95 (96-94) 
95 (95-94) 
Amount of 
dextranase 
(ng) 
147 
19 
154 
153 
% of the dose 
administered 
14.7 
1.9 
15.4 
15.3 
1 /zg of different formulations of dextranase were administered into batches 
of 2 balb/c mice each followed six hours later by 1.5 mg of liposomally 
encapulated FITC-dextran. Animals were sacrificed one hour later. One 
unit of enzyme activity is equal to 1 % decrease in the fluorescence of the 
peak fraction of the untreated control is considered to be 100%. Values are 
given as mean of the two experiments. Range is given within brackets. 
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GEL nLTRATION PROHLE OF nXC-DEXTRAN WHEN ADMIN-
ISTERED 24 HOURS AFTER THE ADMINISTRATION OF VARI-
OUS FORMULATIONS OF DEXTRANASE. 
1 /ig of either dextranase (V ), PEG-dextranase (D ), liposomal dextranase 
( T ) or liposomal PEG-dextranase ( • ) were administered intravenously into 
three Balb/c mice in each group. This was followed 24 hours later by the 
administration of 1.5 mg liposomally encapsulated FITC-dextran. Animals 
were sacrificed after one hour. Livers were removed, washed, weighed, 
homogenised, and subjected to gel filtration on a sephadex G-75 column. 
untreated control ( • ) 
TABLE VI 
AMOUNT OF ENZYME REMAINING IN THE LIVER TWENTY FOUR 
HOURS AFTER ADMINISTERED 
Enzyme formulation 
Dextranase 
PEG-dextranase 
Liposomal 
Dextranase 
Liposomal 
PEG-dextranase 
Enzyme units 
7(3-11) 
21 (23-19) 
4 (8-0) 
64 (69-59) 
Amount of 
dextranase 
(ng) 
11 
34 
6.5 
103 
% of the dose 
administered 
1.2 
3.4 
0.65 
10.3 
1 fig of different formulations of dextranase were administered into batches 
of 2 balb/c mice each followed 24 hours later by 1.5 mg of liposomally 
encapulated FITC-dextran. Animals were sacrificed one hour later. One 
unit of enzyme activity is equal to 1 % decrease in the fluorescence of the 
peak fraction of the untreated control is considered to be 100%. Values are 
given as mean of the two experiments. Range is given within brackets. 
was catalytically active in the liver even after 24 hours of administration, 
compared to only negligible amounts of the other formulations tried. This 
data is similar to that obtained by the radioactivity experiments, once again 
confirming that liposomally delivered PEG-dextranase shows enhanced 
stability in the liver. 
From these results we can say that covalent modification and lipo-
somal encapsulation of dextranase enhances intracellular stability of en-
zymes. The enzyme not only degrades the accumulated substrate, it also 
prevents any further accumulation of the substrate over a period of time. 
Encapsulation into liposomes delivers a larger amount of enzyme into the 
cell. It also enhances the stability of the administered enzyme as can be seen 
by comparing the stability of the free and liposomally encapsulated dextra-
nase. This would be of significance where liver is the organ affected by the 
storage disorder. 
In some cases other tissues such as those of the central nervous 
system and muscle are involved."Homing agents" such as tissue specific 
antibodies will have to be attached to liposomes for specific delivery of the 
entrapped enzyme to the diseased tissue. Work is already progressing rapid-
ly in this directon. Weissmann and coworkers (Weissmann et a/, 1975) have 
shown that attachment of suitable heat aggregated immunoglobulins to lipo-
somal surface greatly enhanced the delivery of the encapsulated hexosamini-
dase- A into leukocytes from patients with Tay Sach's disease. 
The PEG-enzyme conjugates are known to exhibit reduced immuno-
genicity (Lee and Sehon, 1978, Savoca et al, 1979) presumably due to 
reduced recognition and uptake by the cells of the RES. However, not much 
is known about the immunogenicity of these conjugates upon delivery into 
the cell. The potential of lysosomal enzyme therapy using PEG-enzyme 
conjugates will be fiilly exploited only after the effect of intracellular deliv-
ery of the conjugate on its immunogenicity has been studied. 
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SUMMARY 
A model storage condition was developed in the livers of mice by the 
intravenous administration of an undegradable sugar polymer: dextran, 
encapsulated in negatively charged liposomes. Both the free and the lipo-
somally encapsulated dextranase, subsequently administered, could degrade 
this accumulated substrate. Liposomally encapsulated dextranase was more 
effective than the free enzyme in degrading the accumulated substrate. This 
may be due to a more efficient delivery of dextranase into the cells by 
liposomes. 
To establish the effect of covalent modification of enzymes with 
hydrophilic polymers on their intracellular and intralysosomal stability, two 
enzymes horse radish peroxidase (HRP) and dextranase were chosen for 
study. HRP, a mannose-containing glycoprotein was chosen due to the ease 
of its detection. HRP is rapidly taken up by the liver and this uptake is 
markedly inhibited by mannan. After modification with dextran, HRP shows 
an enhanced half life in circulation and its uptake by the liver is consider-
ably reduced. This uptake is also inhibited by mannan although to a lower 
extent than that of the unmodified enzyme. The conjugate therefore partially 
retains its ligand property. This retention of ligand property even after 
modification is important when the ligand depends upon it for its action. 
Due to the different rates of uptake of the free and the modified 
enzyme by the liver, it was not possible to compare their intracellular stabil-
ity. Liposomes were therefore used as carriers for delivering the native and 
the modified enzyme to the liver at similar rates. The liposomally delivered 
dextran-HRP conjugate showed greater catalytic as well as immunological 
stability both intracellularly and intralysosomally compared to free HRP, 
free dextran-HRP and liposomally encapsulated HRP. Almost 40 % of the 
liposomally delivered dextran-HRP conjugate could be detected in the liver 
24 hours after administration compared to negligible amounts of the other 
formulations of HRP tested. 
73 
To study the therapeutic efficacy of such modified enzymes in the 
treatment of a model storage condition, dextranase was modified with PEG. 
The enzyme lost all its activity upon conjugation. The conjugation procedure 
was therfore modified and the reaction was carried out in the presence of the 
substrate, dextran. 25-30% of the enzyme activity was recovered after 
conjugation. Interestingly, although PEG-dextranase shows enhanced half 
life in circulation, small amounts of the conjugate were taken up by the liver 
upon intravenous administration. 
Liposomes were used for delivery of the native and the modified 
enzyme to the liver at similar rates. Liposomally delivered PEG-dextranase 
conjugate showed enhanced intracellular and intralysosomal stability. The 
presence of dextranase inside the cell was monitored both by labeling with 
*^I and by assaying for catalytic activity. The liposomally delivered PEG-
dextranase was capable of both degrading the accumulated substrate as well 
as preventing its further accumulation over a period of time. Only negligi-
ble amounts of the other formulations of dextranase tested, namely free 
dextranase, free PEG-dextranase, and liposomally encapsulated dex-
tranase could be detected in the liver 24 hours after administration. 
This enhanced stability of enzymes upon their extensive glycosyla-
tion with dextran or upon modification with PEG would be of importance in 
extending the catalytic life of therapeutically active enzymes. This would 
improve their therapeutic potential for the treatment of lysosomal enzyme 
deficiency disorders. 
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